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INTRODUCTION TO BREAST CANCER 
Humans have had cancer throughout recorded history. The oldest description 
of cancer (although the word cancer was not used) was discovered in Egypt and dates 
back to about 1600 B.C. It is called the Edwin Smith Papyrus, and is a copy of part of 
an ancient Egyptian textbook on trauma surgery.  The origin of the word cancer is 
credited to the Greek physician Hippocrates (460–370 B.C.), considered the "Father 
of Medicine." Hippocrates used the terms carcinos and carcinoma to describe non-
ulcer forming and ulcer-forming tumors. 
During the Renaissance, famous Scottish surgeon John Hunter (1728–1793) 
said that some cancers cannot be cured by surgery and suggested also how the 
surgeon might decide which cancers to operate on. If the tumor had not invaded 
nearby tissue and was "moveable", he said, "There is no impropriety in removing it‘‘. 
In 19
th
 century there was the use of scientific oncology with modern microscope in 
studying diseased tissues [1].  
Cancer begins when cells in a part of the body start to grow out of control. 
There are many kinds of cancer, but they all start because of out-of-control growth of 
abnormal cells [1].  
Despite years of intensive study and substantial progress in understanding 
susceptibility to breast, this disease remains important cause of death in women. 
However, many recent critical advances — sequencing of the human genome and the 
development of high-throughput techniques for identifying DNA-sequence variants, 
changes in copy numbers, and global expression profiles — have given an 
acceleration at preventing and curing this disease [2]. 
Disease occurs almost only in women, but men can get it, too. Breast Cancer (BC) is a 
malignant tumor that starts from cells of the breast. A malignant tumor is a group of 
cancer cells that may grow into (invade) surrounding tissues or spread (metastasize) to 
distant areas of the body [1].  Most often the tumor involves glandular breast cells in 
the ducts or lobules [3]. Cancer starts when a cell in a part of a body starts to grow up 
out of control. Cancer cell growth is different from other normal cell growth because 
cancer cells do not die but they form new ones, abnormal ones. Another difference 
from normal cells is that the cancer cells can grow in other tissues and that is what 
makes cancer.  Cell becomes cancer cell because of the damage of DNA without 
repairmen like in normal cells [1]. Most patients present with an asymptomatic lump 
discovered during examination or screening mammography. Diagnosis is confirmed 
by biopsy. Primary therapy usually includes surgical excision, often in combination 
with radiation therapy. Physicians can also give adjuvant therapy to kill any cancer 
cells that may have spread, even if they cannot be detected by imaging or laboratory 
tests. Studies have shown that adjuvant therapy for BC may increase the chance of 
long-term survival by preventing a recurrence [3].  
Breast Cancer today is considered a leading cause of morbidity around the 
world, with the statistics showing increasing incidence rates to the levels of an 
epidemic [4,5]. The treatment given for BC is highly variable and dependent on a 
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number of factors including the type, location and amount of disease and the health 
status of the patient. The treatments are designed to either directly kill/remove the 
cancer cells or to lead to their eventual death by depriving them of signals needed for 
cell division. Other treatments work by stimulating the body's own defenses. 
However, despite the available treatment choices available, up to this moment the fact 
remains that there is not a ―cure‖ for BC or cancer in general. Therefore, medical 
scientists around the world are striving to come up with novel treatments that could 































Breast cancer arises when there is an uncontrolled growth of abnormal 
cells in the breast. Most often the tumor involves glandular breast cells in the 
ducts or lobules. The most common sign of breast cancer is a new lump or 
mass. Other possible signs can be redness, swelling, nipple discharge and 
more. Some risk factors of breast cancer can be alcohol, obesity, oral 
hormonal contraceptives, radiation, gender, age, hereditary/genetic aspects, 
estrogen and progesterone receptors.  
Breast cancer can be treated by surgery including mastectomy, 
lymphedema surgery and lumpectomy, by radiation therapy or chemotherapy. 
The novel methods include hormonal therapy using selective estrogen receptor 
modulators like tamoxifen, raloxifene, aromatase inhibitors like anastrozole 
and letrozole.  One of the promising therapies is immune therapy with the use 
of interferons and other cytokines, dendritic cells and vaccines. Another novel 
approach is represented by the targeted therapy that is using monoclonal 
antibodies, tyrosine kinase inhibitors and more promising ways. The gene 
therapy that is made to correct specific molecular defects that contributes to 
the cause or progressions of breast cancer belong also into one of the 
perspective methods for the treatment of breast cancer. Last but not least is the 
stem cells therapy that is working with the replacement of the diseased cells.  
Chemotherapy of breast cancer can be complicated by multidrug 
resistance (MDR), which is caused by various mechanisms including 
increased drug efflux from the cell by ATP dependent transporters, decreased 
drug uptake into the cell, activation of detoxifying enzymes and defective 
apoptotic pathways. The methods to overcome the resistance include control 
of expression of multi drug resistance proteins and suppression of the activity 













AIMS OF THE STUDY 
The aim of this work is to overview current knowledge on breast cancer in 
relation to the diagnosis, screening and methods used to treat the disease, with 
emphasize put on the novel approaches. The main causes of multidrug resistance of 
the cancer and the approaches to overcome this phenomenon are also summarized. 
METHODOLOGY 
All the information in this diploma thesis was obtained from original articles, 
scientific reviews and guidelines retrieved from various search databases and 
webpages. These included mainly PubMed, Merck manual online, 
cancernetwork.com, UBMMedica, BreastCancer.org and pages of American Cancer 
Society (cancer.org). The key words that have been used in order to retrieve the 
relevant literature included: breast cancer, novel treatment, chemotherapy, stem cells, 




































1. Definition and classification of Breast Cancer 
 
Breast Cancer is the most common type of cancer among women worldwide 
and its rate is increasing in both developed and developing countries [4]. The load is 
not evenly distributed and there are large variations in the incidence rates of BC 
between different countries. BC is an uncontrolled growth of breast cells. 
Cancer occurs as a result of mutations, or abnormal changes, in the genes 
responsible for regulating the growth of cells and keeping them healthy. Normally, the 
cells in our bodies replace themselves through an orderly process of cell growth: 
healthy new cells take over as old ones die out. But over time, mutations can ―turn 
on‖ certain genes and ―turn off‖ others in a cell. That changed cell gains the ability to 
keep dividing without control or order, producing more cells just like it and forming a 
tumor. A tumor can be benign (not dangerous to health) or malignant (has the 
potential to be dangerous). Benign tumors are not considered cancerous: their cells are 
close to normal in appearance, they grow slowly, and they do not invade nearby 
tissues or spread to other parts of the body. Malignant tumors are cancerous.  The 
term ―breast cancer‖ refers to a malignant tumor that has developed from cells in the 
breast. Usually BC either begins in the cells of the lobules, which are the milk-
producing glands, or the ducts, the passages that drain milk from the lobules to the 
nipple. Over time, cancer cells can invade nearby healthy breast tissue and make their 
way into the underarm lymph nodes, small organs that filter out foreign substances in 
the body (Table 1). If cancer cells get into the lymph nodes, they then have a pathway 
into other parts of the body. BC is always caused by a genetic abnormality (a 
―mistake‖ in the genetic material). However, only 5-10% of cancers are due to an 
abnormality inherited from your mother or father. About 90% of breast cancers are 
due to genetic abnormalities that happen as a result of the aging process and the ―wear 
and tear‖ of life in general [5]. Most breast lumps which are due to fibrocystic 
changes and other breast complaints are due to benign conditions. Breast pain can be 
produced also by mastitis, pendulous breasts, or hidradenitis suppurativa. Moreover 
they constitute the greatest percentage of symptoms leading to a diagnosis of cancer. 
Nipple discharge is usually benign, especially if non bloody, bilateral, and not 
spontaneous and can be due to medications, hormonal factors, prior nursing or 
pregnancy, or, less commonly, cancer [6]. Many genetic, epidemiologic, and 
laboratory studies support that a series of genetic changes contribute to the dynamic 
process which can cause BC is known as carcinogenesis [7]. Accumulation of these 
genetic changes corresponds to the phenotypic changes associated with the evolution 
of malignancy at the end. The carcinogenesis sequence is starting with tissue of 
normal appearance followed by changes leading to hyperplasia and dysplasia, the 
most severe forms of which are difficult to distinguish from carcinoma in situ [8]. The 
concept that BC may be preventable is supported by the wide international variation 
in BC rates, which is an indicator that there are potentially modifiable environmental 
and lifestyle determinants of breast cancer. Migration studies reinforce this premise; 
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for example, it has been observed that Japanese immigrants to the United States 
increase their BC risk from Japanese to American levels within two generations [9, 
10, 11]. 
Table 1 . Stages of  breast cancer. Adopted from BreastCancer.org [1] 
STAGE DEFINITION 
0 Cancer cells remain inside the breast duct, without invasion into normal 
adjacent breast tissue. 
I Cancer is 2 centimeters or less and is confined to the breast (lymph nodes 
are clear). 
IIA No tumor can be found in the breast, but cancer cells are found in the 
auxiliary lymph nodes (the lymph nodes under the arm)  
OR  
the tumor measures 2 centimeters or smaller and has spread to the auxiliary 
lymph nodes  
OR  
the tumor is larger than 2 but no larger than 5 centimeters and has not spread 
to the auxiliary lymph nodes. 
IIB The tumor is larger than 2 but no larger than 5 centimeters and has spread to 
the auxiliary lymph nodes  
OR  
the tumor is larger than 5 centimeters but has not spread to the auxiliary 
lymph nodes. 
IIIA No tumor is found in the breast. Cancer is found in auxiliary lymph nodes 
that are sticking together or to other structures, or cancer may be found in 
lymph nodes near the breastbone  
OR  
the tumor is any size. Cancer has spread to the auxiliary lymph nodes, which 
are sticking together or to other structures, or cancer may be found in lymph 
nodes near the breastbone. 
IIIB The tumor may be any size and has spread to the chest wall and/or skin of 
the breast  
AND  
may have spread to auxiliary lymph nodes that are clumped together or 
sticking to other structures, or cancer may have spread to lymph nodes near 
the breastbone.  
IIIC There may either be no sign of cancer in the breast or a tumor may be any 
size and may have spread to the chest wall and/or the skin of the breast  
AND  
the cancer has spread to lymph nodes either above or below the collarbone  
AND  
the cancer may have spread to auxiliary lymph nodes or to lymph nodes near 
the breastbone. 





2. Statistics of Breast Cancer 
 
Around 429,900 new cases of BC occur each year in Europe [12]. The lowest 
European rates are in eastern and southern Europe and the highest are in Northern and 
Western Europe (Figure 1). 
 











3. Signs of Breast Cancer 
The most common sign of BC is a new lump or mass. A mass that is painless, 
hard, and has irregular edges is more likely to be cancerous, but breast cancers can be 
tender, soft, or rounded. For this reason, it is important that any new mass, lump, or 
breast change is checked by a health care professional with experience in diagnosing 
breast diseases.  
Other possible signs of BC include:  
 swelling of all or part of a breast (even if no distinct lump is felt)  
 skin irritation or dimpling  
 breast or nipple pain  
 nipple retraction (turning inward)  
 redness, scaliness, or thickening of the nipple or breast skin 
 a nipple discharge other than breast milk [1].  
4. Diagnosis and screening 
The American Cancer Society released the following recommendations for the 
diagnosis of Breast Cancer:  
 Women with age 40 and older should have a mammogram every year 
continuously until they are in good health [1].   
 Women in their 20s and 30s should have a clinical breast exam (CBE) as part 
of a periodic (regular) health exam by a health professional preferably every 3 
years. Starting at age 40, women should have a CBE by a health professional 
every year [1] . 
 Breast self-examination (BSE) should be started for women in their 20s. Any 
report for breast changes should be told to their health professional right away 
[1,2] . 
 Women at high risk (greater than 20% lifetime risk) should get an MRI 
(Magnetic Resonance Imaging) and a mammogram every year. Women at 
moderately increased risk (15% to 20% lifetime risk) should talk with their 
doctors about the benefits and limitations of adding MRI screening to their 
yearly mammogram. Yearly MRI screening is not recommended for women 







5. Risk Factors 
A ―risk factor‖ is anything that has the potential to increase the risk of 
developing cancer. Many of the most important risk factors for BC are beyond one‘s 
control, such as age, family history, gender, estrogen exposure (early menstruation, 
late menopause), estrogen receptors (ER) and progesterone receptors (PR) and 
radiation therapy to chest [6].  However, there are some risk factors that can be 
controlled, such as weight, physical activity, oral contraceptives and alcohol 
consumption and others that cannot be controlled such as gender and radiation [5]. 
5.1 Obesity  
Obesity is an increased BC risk, especially for postmenopausal women that 
did not use Hormonal Therapy (HT). The Woman‘s Health Initiative (WHI) 
observational study observed 85,917 women aged 50 to 79 years and collected 
information on their weight history [13]. Height, weight, and waist and hip 
circumferences were measured. With a median follow-up of 34.8 months, 1,030 of the 
women developed invasive breast cancer. Among the women who never used HT, 
increased BC risk was associated with weight at entry, body mass index (BMI) at 
entry, BMI at age 50 years, maximum BMI, adult and postmenopausal weight change, 
and waist and hip circumferences. Weight was the strongest predictor, with a Relative 
Risk (RR) of 2.85 (95% CI, 1.81–4.49) for women weighing more than 82.2kg, 
compared with those weighing less than 58.7 kg [13]. 
5.2. Alcohol  
Many epidemiologic studies have shown that alcohol consumption is also an 
increased risk of BC. Individual data from 53 case-control and cohort studies were 
included in a British meta-analysis [14]. Compared with women who reported no 
alcohol consumption, the RR of BC was 1.32 (95% CI, 1.19–1.45; P < .001) for 
women consuming 35 g to 44 g of alcohol per day and 1.46 (95% CI, 1.33–1.61; P < 
.001) for those consuming at least 45 g of alcohol per day. The RR of BC increases by 
about 7% (95% CI, 5.5%–8.7%; P < .001) for each 10 g of alcohol (i.e., one drink) 
consumed per day. The same result was obtained, even after additional stratification 
for race, education, family history, age at menarche, height, weight, BMI, breast-
feeding, oral contraceptive use, menopausal hormone use and type, and age at 
menopause. Alcohol can limit liver‘s ability to control blood levels of the hormone 






5.3. Exercise  
 
Active exercise may reduce BC risk, particularly in young women [15, 17]. 
Many observational studies have examined the relationship between physical activity 
and BC risk [16]. Most of these studies have shown that increased physical activity is 
contrast to BC incidence. The average RR reduction is reportedly 30% to 40%. 
However, it is not known to what degree, if at all, the observed association is to the 
result of confounding variables, such as diet or a genetic predisposition to breast 
cancer. A prospective study of more than 25,000 women in Norway suggests that 
doing heavy manual labor or exercising 4 or more hours per week is associated with a 
decrease in BC risk. This result is more for premenopausal women and in women of 
normal or lower-than-normal body weight [15]. In a case-control study of African 
American women, strenuous recreational physical activity (>7 hours per week) was 
associated with decreased BC incidence [15]. The American Cancer Society 
recommends engaging in 45-60 minutes of physical exercise 5 or more days a week 
[17]. 
5.4. Oral Contraceptives-Hormonal risk factor 
Using oral contraceptives (OC), also known as birth control pills (estrogen and 
progesterone), appears to slightly increase a woman‘s risk for breast cancer, but only 
for a limited period of time. Results from 10 studies and one pooled analysis of 54 
studies suggest that the use of OC does not significantly modify the risk of BC among 
women with a familial history of BC [18]; however, evidence from four studies shows 
that some women may be at a greater risk, particularly women who took OCs prior to 
1975. Current evidence shows that women with a family history of BC do not 
increase their disease risk by using OCs [91]. During the period of June 1991-
February 1994 in Italy, other researchers conducted a case control study to examine 
the association between oral contraceptive use and BC risk [20]. Cases comprised 
1991 women aged less than 65 with confirmed BC. Controls included 1899 same-age 
patients at the same network of hospitals as the cases with an acute, non-neoplastic, 
non-hormone-related condition. 18% of cases and 14% of controls had ever used OCs. 
Overall, there was no association between OC use and BC. Very short term OC use (1 
year) had an odds ratio (OR) of 1.3 (borderline significance only). However, women 
who had recently stopped using OCs faced an elevated risk of BC (OR = 1.6 for 1-4 
years since last OC and 1.7 for 5-9 years). Among women who had last used OCs 10 
years ago, the risk of BC was directly related to duration of use (OR = 1.3 for 5 years 
and 1.7 for =or 5 years; p = 0.02 [for the trend]). The OR for women who had last 
used an OC longer than 10 years ago reached unity. Among these women, those that 
used OCs for at least five years had a lower risk of developing BC (OR = 0.66). The 
increased OR for women who had recently ceased using OCs and the apparent 
protection against BC among women who ceased using OCs for at least 10 years 
match the pattern of BC risk noted after a full-term pregnancy. These findings should 




Having radiation therapy to the chest area as a child or young adult as 
treatment for another cancer significantly increases BC risk. The increase in risk 
seems to be highest if the radiation was given while the breasts were still developing 
(during the teen years) [5]. Radiation as a carcinogen can interact with DNA to 
produce a range of mutations. Radiation causes double-strand breaks [21]. Exposure 
to ionizing radiation has clearly been established as one of the risk factors for the 
development of breast cancer. Much data on the relationship between radiation 
exposures and subsequent BC are derived from atomic bomb survivors and women 
who received medical exposures either for diagnostic or therapeutic purposes. 
Although therapeutic radiation is rarely used to treat benign conditions, it remains an 
important and effective treatment modality for a wide range of cancers [22].  
5.6. Gender 
  Being a woman is the most significant risk factor for developing BC. 
Although men can get breast cancer, too, women‘s breast cells are constantly 
changing and growing, mainly due to the activity of the female hormones estrogen 
and progesterone. This activity puts them at much greater risk for Breast Cancer [1, 
2]. 
5.7. Age 
Simply growing older is the second biggest risk factor for breast cancer. From 
the age of 30 to 39, the risk is 1 in 233, or .43%. The risk increases to 1 in 27, or 
almost 4%, by the time that the woman will be in her 60s [5].   
5.8. Hereditary/genetic aspects 
People who have a first degree relative (mother, father, sister) that had BC are 
in high risk of getting BC as well. Twenty percent of BC is familial (family history of 
breast cancer). Approximately 5% to 10% of BC is hereditary; a gene mutation has 
been inherited, which puts the patient at an increased risk of cancer (Figure 2). Two-
thirds of these hereditary cancers occur in individuals with BRCA1 or BRCA2 
mutations, which are germline mutations. The remaining 10% to 15% is due to some 
other factor involving the family, such as an environmental factor, chance, or an 



















5.9. Estrogen and Progesterone receptors 
Estrogen and progesterone receptors are reported as positive or negative. 
Laboratories establish a cutoff point related to the percentage of cells which stain with 
the antibody [5]. If the number of cells which stain is greater than that predetermined 
cutoff point, the result is called positive. If the number is below that number, the 
result is called negative. If hormone receptor status is positive, that predicts two 
things, first, a better overall outcome, and second, a good response to hormonal 
therapy. The meaning of the test in terms of choosing treatment options is much more 
important. The higher the percentage of positive estrogen receptors, the greater the 
chance of responding well to hormonal therapy. The lower the hormone receptor 
positivity, the better response will have to chemotherapy. Pathology report may say 
that the BC cells tested negative for estrogen receptors (ER-), progesterone receptors 
(PR-), and HER2, also called human epidermal growth factor receptor 2 (HER2-). 
Testing negative for all three receptors means ―triple-negative breast cancer.‖ Without 
these receptors, the cancer‘s growth is not likely to be fueled by estrogen or 
progesterone, or by growth signals coming from the HER2 protein. Therefore, triple-
negative BC does not respond to hormonal therapy (such as tamoxifen or aromatase 
inhibitors) or therapies that target HER2 receptors, such as Herceptin (trastuzumab). 


















II. EXISTING AND NEW APPROACHES TO TREAT BREAST CANCER 
1. Introduction to therapy  
Cancer treatment has traditionally been dominated by intravenous drug 
therapy [17]  There has, however, been a constant increase in the production of 
different oral anticancer drugs offering obvious benefits in terms of convenience and 
ease of administration, as well as addressing patients' preference for oral therapy [17 , 
18 , 24, 25]. It is proved that one-quarter of all anticancer agents under development 
are oral agents [26] Several agents that are already approved in a range of tumor types 
(e.g. capecitabine, erlotinib, gefitinib, imatinib, lapatinib, lenalidomide, thalidomide, 
sunitinib, sorafenib) and many others in development (e.g. vatalanib, satraplatin) are 
or will be available only as oral formulations. Novel approaches to drug delivery, 
such as the development of hydrophilic polymer carriers to deliver drugs to the gut 
[27], are likely to further increase the number of oral drugs available promising even 
better results in the deal of Breast Cancer. Remarkable and additional to this is to say 
that therapy is also based on the fact that cells have receptors on their surface and in 
their cytoplasm and nucleus. Chemical messengers such as hormones bind to 
receptors, and this causes changes in the cell. BC cells may or may not have three 
important receptors: estrogen receptor, progesterone receptor (PR), and HER2/neu. 
Cells with these receptors are called ER positive (ER+), ER negative (ER-), PR 
positive (PR+), PR negative (PR-), HER2 positive (HER2+), and HER2 negative 
(HER2-). Cells with none of these receptors are called basal-like or triple negative. 
ER+ cancer cells depend on estrogen for their growth, so they can be treated with 
drugs to reduce estrogen (e.g. tamoxifen), and generally have a better prognosis. 
Generally, HER2+ had a worse prognosis, however HER2+ cancer cells respond to 
drugs such as the monoclonal antibody, trastuzumab, (in combination with 
conventional chemotherapy) and this has improved the prognosis significantly. That is 
why scientists have done the estrogen receptor assay that is a laboratory test done on a 
sample of the cancer in order to see whether estrogen receptors are present. The 
growth of normal breast cells and some breast cancers is stimulated by estrogen. BC 
cells without these receptors (called estrogen-receptor negative or ER negative) are 
unlikely to respond to hormonal therapy. Estrogen-receptor positive cancers are more 
likely to respond to hormonal therapy.  Since estrogen nourishes some types of breast 
cancer, scientists question whether estrogen replacement therapy increases the Breast 







2.  Surgery  
2.1 Mastectomy 
 
For the first 80 years of the last century, mastectomy was considered to be the 
choice of most of the women with newly diagnosed, early stage of BC for their 
treatment. For more than 3 decades breast-conserving surgery in the treatment of BC 
has been proved by randomized controlled trials and meta-analysis trials to be safe. 
These have all shown equivalent long-term survival in women treated with breast-
conserving surgery or mastectomy [28, 29 , 30 , 31 , 32]. 
Mastectomy can be used when breast conservation therapy is not possible (due 
to a large or multicentric tumor) or would result in poor cosmetic outcome, or when 
the patient specifically chooses a mastectomy. Simple Mastectomy involves removal 
of breast only without removal of lymph nodes. Skin sparing mastectomy performed 
when patient undergoes immediate breast reconstruction. The goal is to remove all 
breast tissue, along with the nipple-areola complex. The procedures Nipple-areola–
sparing mastectomy attempt to preserve either the whole complex, termed nipple 
areola–sparing mastectomy or just the areola, with removal of the nipple [32, 33]. 
 
2.2. Lymphedema surgery 
Lymphedema is defined as the excessive and persistent accumulation of fluid 
and extravascular and extracellular proteins in tissue spaces, due to the inefficiency of 
the lymphatic system [34]. Surgery and Radiotherapy of BC can be accompanied by 
auxiliary lymph node drainage, which may cause upper limb lymphedema. [34, 35, 
36, 37] . It is extremely important to reduce and control lympedema due to the 
severity of complications resulting from post-surgical lymphedema. It can be 
significantly reduced during the first week of treatment and less significantly after the 
third week [38] reducing in this way the incidence of probable infections. 
Physiotherapy resources for lymphedema treatment are for example complex 
decongestive therapy (CDT), pneumatic compression (CP), high voltage electrical 
stimulation (HVES) and laser therapy (LT). 
2.3. Lympectomy 
It is a common surgery that involves the removing of the lump of the Breast 
Cancer and the surrounding tissue without removing the entire breast. It is a less 
radical procedure than mastectomy and is usually followed by radiotherapy (RT). 
Comparing to mastectomy, as the tissue is removed the procedure is generally quite 
limited and non-invasive. A lumpectomy is considered a viable means of "breast 
conservation" or "breast preservation" surgery with all the attendant physical and 
emotional advantages of such an approach. Lumpectomy may be performed for ductal 
carcinoma in situ (DCIS), for invasive ductal carcinoma, or for other conditions. 
24 
 
3. Radiaton Therapy 
Radiation therapy is an adjuvant treatment for most women and is following 
lumpectomy and mastectomy surgery. Management of Breast Cancer requires a 
multimodality approach and an integration of the services of surgery, radiotherapy 
(RT), and chemotherapy. Recent reports have shown not only the established two-
thirds reduction in local recurrence when RT is used after mastectomy or breast 
conserving surgery (BCS), but also an overall survival benefit of around 5-10% [28, 
39, 40] raising in that way the use of  Radiation therapy after the undergo of  
mastectomy and/or lumpectomy surgery. 
Radiotherapy can be delivered in many ways but the most common way is by 
a linear accelerator. Currently it is set that for stage T1, T2 breast cancer, patients with 
at least four positive auxiliary nodes should receive postoperative radiotherapy of the 
chest wall and lymphatic drainage area, and patients with negative auxiliary nodes 
need no radiotherapy after mastectomy [41, 42]. However, whether patents with one 
to three positive auxiliary nodes need postoperative radiotherapy after mastectomy 
has been controversial [43]. Radiation as in other therapeutic approaches to treat 
cancer has various side effects which may include muscle stiffness, mild swelling and 
tenderness in the area.  
4. Chemotherapy 
Chemotherapy (drug treatment for cancer cells throughout the body) may be 
used before surgery, after surgery, or instead of surgery for those cases in which 
surgery is considered unsuitable. Multiple chemotherapeutic agents may be used in 
combination to treat patients with breast cancer [44]. Determining the appropriate 
regimen to use depends on many factors; such as, the character of the tumor, lymph 
node status, and the age and health of the patient. In general, chemotherapy has 
increasing side effects as the patient's age passes the age of 65 [45, 46]. 
There are three major types of chemotherapy. 
 Neoadjuvant chemotherapy  
Given before surgery to minimize the size of a tumor     
 Adjuvant chemotherapy  
Given after surgery to decrease the risk of recurrence of cancer cells. Some of the 
drugs used for adjuvant therapy include the single use or the combinations of the 





 Palliative chemotherapy  
Given to control (but not cure) the cancer in settings in which the cancer has spread 
beyond the breast and localized lymph nodes. 
Taxanes  
Taxanes are between the most active chemotherapeutic agents used to treat 
metastatic breast cancer. They have a novel mechanism of action and non-cross 
resistance (see chapter on Multi Drug Resistance – MDR) with anthracyclines 
provides a sound rationale for testing their activity in the adjuvant setting. The 
addition taxanes appears to improve disease-free and overall survival (OS) in women 
with early-stage breast cancer, independently of receptor expression and lymph node 
involvement [41]. Today, there are too many different choices for the therapy of early 
stage BC than for any other type of cancer in humans.  Despite this fact, that there is a 
broad armamentarium of therapy, it is still stays considerable uncertainty regarding 
the optimal therapeutic strategy for each individual patient. Although the precise role 
of taxanes is somewhat uncertain, based upon the data from first-generation taxane 
trials it is reasonable to consider taxane therapy in women that have an elevated risk 
of relapse where endocrine sensitivity is absent or incomplete. In the future, it may be 
possible to limit anthracyclines to particular subgroups of patients with specific 
molecular alterations, such as co-amplification of HER-2 and TOP2A. Amplification 
of the HER-2/NEU oncogene (17q12-q21), which encodes a transmembranous 
tyrosine kinase, has been described in numerous solid tumors, including breast, colon, 
endometrium, lung, ovary, stomach, thyroid and bladder cancers, and has been 
associated with short survival in patients suffering from breast, lung and ovary tumors 
[47-49]. The TOP2A is an essential nuclear enzyme involved in DNA replication by 
regulating transient breakage and rejoining of double-stranded DNA. Subsequent 
studies revealed that TOP2A is located adjacent to the HER-2 gene and suggested that 
coamplification or deletion of TOP2A may be responsible for the altered 
chemosensitivity of some HER-2-amplified tumors [49-52]. However, further 
prospective data are required before anthracyclines can be routinely omitted in 
patients who do not harbor such biomarkers. For patients with HER-2-positive 
disease, adjuvant trastuzumab therapy has a clearly established benefit, in spite of the 
recent negative findings from the PACS 04 trial [53, 54]. 
Doxorubicin 
In the efforts to treat Breast cancer the conventional anthracyclines appear to 
be the most widely used agents both as an adjuvant treatment, as well as in metastatic 
disease. In the literature there is evidence studies that doxorubicin presents many 
advantages such as its response rate, time to disease progression, and overall survival 
of the patients‘ receiving this kind of treatment. 
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Despite the fact that doxorubicin has excellent antitumor activity, it has also a 
relatively low therapeutic index, and its use is limited by myelosuppression, alopecia, 
acute nausea and vomiting, stomatitis, and above all cumulative cardiotoxicity  [48]. 
Early studies have shown promise with liposomal doxorubicin and pegylated 
liposomal doxorubicin (PLD) as neo-adjuvant therapy in patients with locally 
advanced Breast Cancer [50] or in combination with trastuzumab [52]. In fact, 
combination of trastuzumab with liposomal anthracyclines currently under 
investigation have shown better cardiac safety than that observed when trastuzumab 
was combined with conventional doxorubicin [54, 55]. 
5.  Hormonal Therapy 
Tamoxifen - selective estrogen receptor modulators (SERMs)  
Some new drugs called selective estrogen receptor modulators (SERMs) are 
being studied. They seem to have many of the helpful effects of estrogen replacement 
without increasing Breast Cancer risk; in fact, recent studies suggest that some 
SERMs may actually reduce BC risk [1] Also they have done the progesterone 
receptor assay which is not as important clinically as ER. It is a laboratory test done 
on a sample of the Breast Cancer that shows whether the cancer depends on 
progesterone for growth [1]. It can provide useful information and should also be 
performed on all samples of invasive BC or DCIS [56].  Progesterone and estrogen 
receptor tests provide more complete information to help decide the best cancer 
treatment for the patient [1].                                
Tamoxifen is one of the important discoveries in the use of synthetic selective 
estrogen modulators (SERMs) in the treatment strategy for estrogen receptor (ER)-
positive breast cancer. Hundreds of thousands of lives have been saved because of this 
advanced discovery. Tamoxifen it is used as we said in the treatment of Breast Cancer 
but also it is used for prevention in high-risk premenopausal women [57]                                                
Tamoxifen, is the first targeted agent for the treatment of Breast Cancer [57] that 
according to its results it is saving thousands of lives. Its use has significantly 
contributed to a reduction in BC mortality, because Breast Cancer patients that have 
been treated with TAM for 5 years exhibit a 30-50% reduction in both the rate of 
disease recurrence after 10 years of patient follow-up and occurrence of contralateral 
breast cancer. However, in patients treated with TAM there is substantial 
interindividual variability in the development of resistance to TAM therapy, and in 
the incidence of TAM-induced adverse events, including deep vein thrombosis, hot 
flashes, and the development of endometrial cancer. [58] The laboratory strategy of 
tamoxifen is targeting OER positive tumors [59] with long-term adjuvant therapy [48, 
49] ultimately resulted in the improved survivorship of hundreds of thousands of 
women around the world. Indeed, the fact that tamoxifen is cheap and accessible to 
under-funded healthcare systems worldwide means that this form of targeted therapy 
continues to save lives till today. However, unlike the targeted therapies of today that 
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usually have a single anticancer application, tamoxifen became the gold standard for 
the targeted therapy of all stages of Breast Cancer (including male breast cancer), the 
treatment of ductal carcinoma in situ [59] a pioneering agent for the chemoprevention 
of BC in high risk women [58, 59] and the lead compound for the new drug group, the 
SERMs [57, 59]. The extensive laboratory studies of tamoxifen and the related 
nonsteroidal antioestrogen LY156,758 (keoxifene) undertaken as a prelude to 
initiating major trials in BC prevention, described the pharmacology of SERMs that 
switch on and switch off target sites throughout the body. As an example of the 
immediate translation of the discovery of SERM action, tamoxifen was noted to block 
Breast Cancer growth but enhances the growth of endometrial cancer growth under 
laboratory conditions [59] .This laboratory concept translated to improved clinical 
care through awareness that tamoxifen increased the incidence of endometrial cancer 
in postmenopausal women treated for breast cancer. 
Clinical Implications of CYP2D6 in Tamoxifen Treatment for Breast Cancer 
 
Recently the Food and Drug Administration (FDA) recommended an update in 
the label of Tamoxifen and o make it to show the increased risk of recurrence in BC 
patients that have cytochrome P450 (CYP2D6) poor metabolized. Six studies were 
analysed, and three of them were found consistent with FDA recommendations. The 
CYP2D6 genotype might be one of the first predictors of therapeutic response in 
cancer care based on germline DNA creating the possibility to analyze blood instead 
of tumor [86, 173].  
 
The study design and main results of the six studies are summarized in Tables 
4 and 5. The results by Goetz [174] Schroth [175] and Gonzalez-Santiago [174] all 
show lower recurrence-free survival in poor metabolizers compared with extensive 
metabolizers. The results presented by Nowell [177] and by Wegman in her 2005 
publication [178] fail to show any association, whereas in 2007 Wegman [179] shows 
an even better recurrence-free survival in poor metabolizers. All studies combined the 
heterozygous genotypes (e.g. *1/*4 or *1/*41) either with the poor metabolizers (e.g. 
*4/*4) or with the homozygous wild-type genotype (*1/*1). A total of 471 tamoxifen-
using patients were genotyped and included in the Goetz, Schroth, and Gonzalez-









Table 4. ‗‗Positive‘‘ studies on mainly Caucasian Breast Cancer patients using adjuvant tamoxifen: 







    N 
 
Results 
Goetz et al. 2005  [174]  *4/*4 vs. 1/*1 + 
*1/*4 
190 RFS HR, 1.86; P = 0.08 
Goetz et al. 2007  [174]  197 RFS HR, 1.74; 
P=0.02(+CYP2D6inhibit
ors)      
Schroth et al. [175] Rest (*4,*5, *10, 
*41)* vs. *1/*1 
19
7 
EFS HR, 1.89; P = 0.02 
Gonzalez-Santiago et 
al. [176] 






RFS HR, 2.82; P = 0.05 
 
Abbreviations: N, number of patients; RFS, recurrence-free survival; EFS, event-
free survival; HR, adjusted hazard ratios. 
* Rest group includes all heterozygous and homozygous variant genotypes. 
C Abstract at 2007 ASCO Annual Meeting. 
 
Table 5. ‗‗Negative‘‘ studies on mainly Caucasian BC patients using adjuvant tamoxifen: lower 
recurrence in Poor Metabolizers. Adapted from Vincent O. Dezentje,  et al. [180] 
 
Author (population) Study design N Results 





DRFS HR, <1; 
 
          nonsignificant 
Wegman et al. 2007  [178] *4/*4 vs. *1/*4 or 
1/*1 
677 RFS HR, <1; P = 
0.055 
Nowell et al. [177] *4/*4 + *1/*4 vs. 1/*1 162 PFS HR, 0.67; P = 
0.19 







Raloxifene is a second-generation selective estrogen receptor modulator 
(SERM) that acts as an estrogen antagonist on breast and uterine tissues, and an 
estrogen agonist on bone. Raloxifene reduces the risk of invasive Breast Cancer in 
postmenopausal women at high risk of invasive Breast Cancer and in postmenopausal 
women with osteoporosis. There in the risk of invasive Breast Cancer achieved in 
postmenopausal women at high risk of such cancer. Raloxifene was associated with 
an increased, albeit rare, risk of venous thromboembolism from 1.5- to 3-fold [60], 
across several placebo-controlled trials and an increased risk of fatal stroke in one 
placebo-controlled trial in postmenopausal woman at increased risk for major 
coronary events. However, raloxifene was associated with a lower risk of venous 
thromboembolic events and cataracts than tamoxifen in a head-to-head trial [61].  
Among these adverse effects, the most noteworthy is a 7% increase in hot flashes in 
the initial postmenopausal period [60] . Another adverse reaction that has been 
observed is leg cramps. Cardiovascular risks were assessed in RUTH (Raloxifene Use 
for the Heart Trial) study [60] this was a randomized, double-blind, placebo-
controlled, international study which was conducted in postmenopausal women at risk 
for major coronary events. A total of 10,101 postmenopausal women with established 
coronary heart disease or at increased risk for coronary heart disease were randomly 
assigned to either placebo (N = 5057) or raloxifene 60 mg/day (N = 5044). Raloxifene 
treatment neither increased nor decreased the risk of coronary events. Insofar as 
genitourinary safety is concerned, raloxifene did not cause endometrial hypertrophy 
nor increased the risk vaginal bleeding [60]  In fact, in the clinical trials in which 
raloxifene   (n = 317) was compared to continuous combined hormone replacement 
therapy (n = 110) or with cyclic hormone replacement therapy (n = 205), the 
incidence of breast symptoms and uterine bleeding in the women treated with 
raloxifene was significantly lower than in the women treated with either of the two 
hormone replacement therapy (HRT) regimens. Raloxifene should not be 
administered to pregnant women or to men, since its innocuousness has not been 
demonstrated in these patients. One example of the application of SERMs, a failed 
drug for Breast Cancer, keoxifene, was reinvented [57,59] as raloxifene, the first 
SERM to be successfully used to treat osteoporosis with the beneficial side effect of 
preventing BC indirectly [60, 59] It should be stressed, however, that raloxifene 
cannot be used to reduce Breast Cancer risk in premenopausal women. Raloxifene is 
as effective as tamoxifen in reducing the risk of invasive Breast Cancer [62]. 
Comparison of tamoxifen and raloxifen  
The NSABP Study of Tamoxifen and Raloxifene (STAR), was designed in 
order to compare the tamoxifen with raloxifene in a population of healthy 
postmenopausal women at increased risk for Breast Cancer [63].  
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The study was undertaken between July 1999 and November 2004, and in 
total 19,747 women was randomized to receive either tamoxifen (20 mg, plus 
placebo) or raloxifene (60 mg, plus placebo) daily for a 5-year period. The mean 
predicted 5-year risk of developing Breast Cancer among the study population was 
4.03% (SD, 2.17%) with a lifetime predicted risk of 16%. The mean time of follow-up 
was 3.9 years (SD, 1.6 years).  
In this report of the STAR trial, raloxifene and tamoxifen were equivalent in 
efficacy for lowering the risk of invasive breast cancer [61, 62]. The cumulative 
incidence rates were 25.1 per 1000 Women (raloxifene) vs 24.8 per 1000 (tamoxifen) 
(P=.83). 
There were fewer cases of noninvasive BC (LCIS and ductal carcinoma in situ 
[DCIS]) in the tamoxifen group (57 cases) than in the raloxifene group (80 cases), 
although the difference is not yet statistically significant (incidence 1.51 vs 2.11 per 
1,000; RR, 1.40; 95% CI, 0.98-2.00). There were 36 cases of uterine cancer with 
tamoxifen and 23 cases with raloxifene (RR, 0.63; 95% CI, 0.35-1.08). [59] Both 
tamoxifen and raloxifene are known to increase a woman's risk of blood clots (see 
table 2).  
Consistent with preclinical findings and with results from other large-scale 
studies showing that, compared with placebo, raloxifene does not increase 
endometrial cancer risk,[64, 65] the rate of endometrial cancer in the STAR trial, 
although not statistically significant, was 38% lower in the raloxifene group than in 
the tamoxifen group [61]. In contrast to tamoxifen, raloxifene does not reduce the risk 
of noninvasive breast cancer. Raloxifene also was associated with significantly less 
risk of thromboembolic events and cataracts (see table 2) [66]. Combined, these 
results demonstrate that raloxifene is an alternative for lowering risk of invasive 
breast cancer in postmenopausal women with higher Gail risk scores and in those with 










Table 2: Safety outcomes from the STAR trial2. Adopted from Evista [71] 
SAFETY OUTCOMES FROM THE STAR TRIAL 2 
 TAMOXIFEN EVISTA 
Uterine Cancer 36 cases of uterine cancer 23 cases of uterine cancer 
Uterine hyperplasia 
‡
 84 cases of uterine 
hyperplasia 




 244 hysterectomies 111 hysterectomies 
Ishemic Heart Disease 114 cases 126 cases 





141 cases of deep vein 
thrombosis and 
pulmonary embolism 
100 cases of deep vein  
thrombosis and pulmonary 
embolism 
Fractures 104 cases of 1 type of 
fracture; 26 hip fracture 
96 cases of 1 type of fracture;   
23 hip fractures 
Cataracts 
‡
 394 cases of cataracts;  
260 cataracts  surgeries 
313 cases of cataracts; 
215 cataracts surgeries 
Deaths 101 deaths 96 deaths 
(‡)
The highlighted rows depict areas where the difference between treatment groups 












Many breast tumors are "estrogen sensitive," meaning the hormone estrogen helps 
them to grow. Aromatase inhibitors (AIs) can help block the growth of these tumors 
by lowering the amount of estrogen in the body. AIs are categorized into two types 
[65]:  
 Irreversible steroidal inhibitors such as exemestane form a permanent bond 
with the aromatase enzyme complex. 
 Non-steroidal inhibitors (such as anastrozole, letrozole) inhibit the enzyme by 
reversible competition. 
Aromatase inhibitors are effective and well tolerated drugs in the endocrine 
therapy of estrogen-receptor positive Breast Cancer in postmenopausal women. The 
long-term side effects and the safety of aromatase inhibitors still remain to be seen, 
and studies have been designed towards this direction. The most commonly used 
aromatase inhibitors include Aminoglutethimide, Testolactone, Anastrozole, 
Letrozole, Vorozole, Formestane and Fadrozole 
The results of ongoing studies may indicate the role of aromatase inhibitors in the 
prevention of breast cancer. Many tests on chemoprevention of mammary 
carcinogenesis in female rats have been shown desirable effects of aromatase 
inhibitors--anastrozole and letrozole in premenopausal women affected by breast 
cancer [67] . The third-generation aromatase inhibitors (AIs) anastrozole, exemestane 
and letrozole have largely replaced tamoxifen as the preferred treatment for hormone 
receptor - positive BC in postmenopausal women [64] due to their superiority shown 
in several recent head-to-head trials [65].                                        
Statistics show that approximately 185,000 new cases of invasive BC and are 
recorded each year and from these cases at least half are eligible for adjuvant therapy 
with AIs [67]. In addition, AIs are currently being tested as primary prevention 
therapy in large randomized trials involving tens of thousands of women at increased 
risk for breast cancer. Given the volume of use, internists will increasingly see 
postmenopausal women who are taking or considering treatment with AIs. Physicians 
need to be able to: (a) briefly discuss the advantages and the disadvantages of using a 
selective estrogen receptor modulator such as tamoxifen or raloxifene instead of an AI 






Side Effects of Aromatase Inhibitors 
Systemic adjuvant therapy has proven to be significantly effective at reducing 
recurrences and deaths in patients who have received primary therapy for early breast 
cancer. However, as with all treatments, adjuvant therapy can cause some unwanted 
side effects. With the presence of side-effects the importance of their effective 
management and control becomes apparent. Only this way one can achieve the 
compliance of patients with the treatment. Adjuvant endocrine therapy can be taken 
for many years because is not associated with the more severe, acute toxicities of 
chemotherapy. As it is known, the standard duration of postoperative adjuvant 
endocrine therapy is approximately 5 years. Prevention and treatment of adverse 
events associated with long-term endocrine therapy is particularly important in the 
adjuvant setting, where patients are clinically cancer free [68]. Anastrozole, 
exemestane, and letrozole - are generally well tolerated.  
Most side-effects are mild to moderate and common to menopause [73]. The 
most commonly reported adverse events associated with adjuvant AI therapy include 
hot flushes and musculoskeletal complaints/arthralgia [73, 70]. In contrast to 
tamoxifen, they do not increase the risk of serious life-threatening thromboembolic or 
cerebrovascular events or endometrial cancer. However, there is a small but 
significant increase in the risk of osteoporosis and fractures with AI therapy [74]. An 
adequate monitoring of bone mineral density (BMD) and lipid profile could be 
recommended for post-menopausal women candidate to AIs. Sexual dysfunction is 
one of the side-effects too. The AI-associated reduction in estrogen levels can 
increase vaginal/vulvar symptoms and adversely influence sexual function. Although 
non-hormone-containing local agents with demonstrated efficacy are available, 
optimal therapy for estrogen deprivation-associated vaginal/vulvar symptoms might 
require local or systemic estrogen use. However, the use of systemic estrogen in the 
breast cancer, especially for women on AIs, has been challenged by recent 
randomized clinical trial evidence. In addition, maintenance of estrogen levels in the 
postmenopausal range cannot be assured with local estrogen use. Thus, for 
postmenopausal women with limiting vaginal/vulvar symptoms on adjuvant AIs that 
are not manageable with non-hormone-containing agents, a switch to tamoxifen might 
be preferred rather than adding local or systemic estrogens to the AI regimen [75].  
6. Immune Therapy 
Immune system is the way to effectively protect our body from scavenging 
germs every day. Without it we would be all time effected by different bacteria, 
viruses, protozoa, parasites and fungi. Also cancer is very easy to be developed too. 
We now understand that there is a firm link between the immune system and cancer, 
and that by properly stimulating the immune system we can impact many cancers. 
Through the years immune system has proved to be a standard treatment for variety of 
cancers. Monoclonal antibodies, immune adjuvants, and vaccines against oncogenic 
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viruses are now well-established cancer therapies. Immune modulation is a principal 
element of supportive care for many high-dose chemotherapy regimens. In addition, 
immune activation is now appreciated as central to the therapeutic mechanism of bone 
marrow transplantation for hematologic malignancies [181]. 
Interferons and other cytokines 
In recent decades many advances have occurred in the understanding of the 
role of cytokines in breast cancer [76]. New signaling pathways of interleukin (IL)-1 
family, IL-6, IL-11, IL-18, interferons (IFNs) and interferon regulatory factors 1 
(IRF-1) and 2 (IRF-2) have been found within tumor microenvironments and in 
metastatic sites. Some cytokines (IL-1, IL-6, IL-11, TGFbeta) stimulate while others 
(IL-12, IL-18, IFNs) inhibit BC proliferation and/or invasion. Similarly, high 
circulating levels of some cytokines seem to be favorable (soluble IL-2R) while others 
are unfavorable (IL-1beta, IL-6, IL-8, IL-10, IL-18, gp130) prognostic indicators. So 
far IL-2, IFNalpha, IFNbeta and occasionally IFNgamma, IL-6, IL-12 have been the 
cytokines used for anti tumor treatment of advanced BC either to induce or increase 
hormone sensitivity and/or to stimulate cellular immunity [77]. Disappointing results 
occurred in most trials; however, two long-term pilot studies suggest that IL-2 and 
IFNbeta, when used appropriately can have a positive effect on clinical benefit and 
overall survival of patients with minimal residual disease after chemotherapy or with 
disseminated disease controlled by conventional endocrine therapy [77]. Cytokines 
play a major role in the immune response to tumors. Single nucleotide polymorphisms 
(SNPs) in the regulatory or coding regions of many cytokine genes lead to functional 
alterations in the transcriptional regulation of these genes or the proteins they encode 
[78].   
Distant metastases from Breast Cancer are incurable. In endocrine-responsive 
patients antiestrogens are commonly administered as first and second line therapy. 
Regrettably, tumor growth becomes resistant to this relatively innocuous therapy. 
Beta-interferon was unsuccessfully added to tamoxifen to induce estrogen receptor 
enhancement. In mice, interleukin-2 added to tamoxifen increased their mutual anti-
tumor activities. Nevertheless, no effective clinical application has been developed. It 
started an exploratory clinical trial based on the association of these 
immunostimulating cytokines with antiestrogens for first line salvage therapy of 
hormone dependent BC with distant metastases. Twenty-six consecutive BC patients 
with distant metastases, 23 of which had metastases at multiple sites, were studied for 
responsiveness to treatment with first line salvage antiestrogen therapy, combined 
with beta-interferon and interleukin-2 immuno-therapy. Clinical response and survival 
were compared with that of 30 consecutive historical control patients treated with 
antiestrogen therapy alone. Controls showed, as expected, a median duration of 
response, a median survival time after treatment, and after diagnosis of distant 
metastases, of 16, 31 and 34 months, respectively. After a mean follow-up of 62+/-36 
months (range 17-155), the interval times in the non-control patients were 61 
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(P<0.001), 101 (P<0.000001) and 106 (P<0.000001) months. Two long-term 
survivors appeared to be cured after 155 and 94 months from the time of diagnosis 
with multiple bone metastases. Nineteen of the patients treated with beta-interferon 
and interleukin-2 have survived. Hormone immuno-therapy was given in an 
outpatient setting and was very well tolerated [77, 79]. 
Vaccines for Breast Cancer 
A true cancer vaccine contains cancer cells, parts of cells, or pure antigens. 
The vaccine increases the immune response against cancer cells that are already 
present in the body. It may be combined with other substances or cells called adjuvant 
that help boost the immune response even further [1, 2,  6] . 
Tumor cell Vaccines 
Tumor cell vaccines are made up of actual cancer cells that have been 
removed during surgery. The cells are treated in the lab, usually with radiation, so 
they cannot form more tumors. In most cases, doctors also change the cells in certain 
ways, often by adding chemicals or new genes, to make them more likely to be seen 
as foreign by the immune system. The cells are then injected into the patient. The 
immune system recognizes antigens on these cells, then seeks out and attacks any 
other cells with these antigens that are still in the body.  
MUC-1 
Multiple clinical trials have also tested the safety and bioactivity of vaccines 
that target MUC-1-derived peptide or carbohydrate epitopes.[82] One group of trials 
tested a MUC-1 tandem repeat peptide-KLH conjugate given with the immunologic 
adjuvant QS-21 (a saponin) to patients with stable metastatic breast cancer. This 
vaccination strategy induced antigen-specific IgM and IgG antibody titers associated 
with NK-directed antibody- dependent cellular cytotoxicity (ADCC) as measured in 
vitro. Although concomitant KLH-specific T cell immunity was also induced, no 
evidence of MUC- 1-specific T cell immunity was found [82]. 
 
Dedritic Cells 
Dendritic cells (DC) are recognized as the most potent antigen-presenting cells 
with the ability to stimulate naive resting T cells and to initiate primary immune 
responses [83,84]. Encouraging results in vaccination studies in animal models and 
the development of protocols to generate sufficient numbers of human DC for clinical 
application have led to attempts to verify the feasibility and efficacy of this approach 
in patients in the context of Phase I/II vaccination trials [83]. There has been a surge 
of interest in the use of dendritic cell (DC) vaccination as cellular immunotherapy for 
numerous cancers [84]. Results from early clinical trials pointed to a need for 
additional improvement of DC-based vaccines before they could be considered as 
practical alternatives to the existing cancer treatment strategies. In this regard, 
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subsequent studies have shown that DCs that express transgenes encoding tumor 
antigens are more potent primers of antitumor immunity both in vitro and in vivo than 
DCs simply pulsed with tumor peptides. Furthermore, DCs that have been engineered 
to express certain cytokines or chemokines can display a substantially improved 
maturation status, capacity to migrate to secondary lymphoid organs in vivo, and 
abilities to stimulate tumor-specific T cell responses and induce tumor [85]. 
7. Targeted Therapy of Breast Cancer 
A monoclonal antibody known as Trastuzumab (Herceptin) is used to block 
the action of HER2 protein in Breast Cancer cells and slow down their growth in 
patients whose cancer expresses an over-abundance of the HER2 protein. 
Trastuzumab can be used in combination with chemotherapy in advanced therapy and 
so can both delay cancer growth as well as improve the recipient's survival [72]. More 
recently, several clinical trials have also confirmed that in the adjuvant setting i.e. 
postoperative following BC surgery, the use of trastuzumab for up to one year also 
delays the recurrence of BC and improves survival [59] making the patient less 
worried for re-occurrence. 
Other types of antibodies that are being researched to fight cancer include: 
 Angiogenesis inhibitors. These antibodies prevent the growth of new blood 
vessels, cutting off the supply of oxygen and nutrients to cancer cells [86,87]. 
 Signal transduction inhibitors. These antibodies block signals inside the cancer 
cell that helps the cells divide, stopping the cancer from growing [88, 89]. 
Trastuzumab 
Trastuzumab (Herceptin) is a humanized IgG(1) kappa monoclonal antibody, 
specifically targeted against the extracellular domain of the human epidermal growth 
factor receptor 2 (HER2), and is indicated for the treatment of HER2-positive early or 
metastatic breast cancer [73]. Trastuzumab, when administered concurrently with 
chemotherapy regimens, consistently prolonged disease-free survival (primary 
endpoint) and overall survival (secondary endpoint) in patients with HER2-positive 
early breast cancer. Trastuzumab was generally well tolerated when added to, or 
administered following, a chemotherapy regimen in clinical trials. While cardiac 
adverse events, such as a decreased left ventricular ejection fraction and congestive 
heart failure, are a concern, these effects are treatable and appear to be mostly 
reversible [73].   Therefore, major guidelines recommend using trastuzumab as a key 
drug in the management of HER2-positive metastatic breast cancer. Despite the 
encouraging results obtained with this humanized monoclonal antibody directed 
against the HER2-receptor, used alone or in association with chemotherapy in 
metastatic patients, progression under trastuzumab are usually observed and 
resistances to this treatment are described [74]. Thus, many other monoclonal 
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antibodies and tyrosine-kinase inhibitors emerged. (antiangiogenic therapy )These 
therapeutics, used alone or in association with chemotherapy or trastuzumab have 
variable properties: anti-HER2 and anti-EGFR such as lapatinib, pertuzumab and 
neratinib; anti-EGFR such as gefitinib; antiangiogenesis (bevacizumab); anti-mTOR 
pathway (temsirolimus, everolimus) or inhibitor of HSP90 (tanespimycine) [74]. 
HSP90 (tanespimycine) 
Heat shock protein 90 (HSP90) is the core of a multi-chaperone complex 
critical for the folding, trafficking, and stabilization of many client proteins that are 
involved in tumor cell proliferation, survival, and angiogenesis [90,91] .Targeting 
HSP90 results in degradation of these client proteins. Tanespimycin can be given 
safely at biologically active doses with mild toxicity such as nausea, vomiting, 
diarrhea, and fatigue. Further development of HSP90-targeted strategies includes 
testing of novel chemical structures having better solubility and stability and the 
potential for oral administration. Targeting of HSP90 in combination with other heat 
shock proteins, such as HSP70 or HSP27, may be an alternative strategy that warrants 
further exploration [88].  Phase I study examined whether a heat shock protein (Hsp) 
90 inhibitor tanespimycin (17-AAG; KOS-953) could be administered safely in 
combination with trastuzumab at a dose that inhibits Hsp90 function in vivo in 
lymphocytes. Patients with an advanced solid tumor progressing during standard 
therapy were eligible. Patients were treated with weekly trastuzumab followed by 
intravenous tanespimycin, assessed in escalating dose levels. Twenty-five patients 
were enrolled onto four tanespimycin dose levels: 225 (n = 4), 300 (n = 3), 375 (n = 
8), and 450 mg/m2 (n = 10). Dose-limiting toxicity (DLT) was observed at the third 
and fourth cohort (1 patient each): more than 2-week delay for grade 4 fatigue/grade 2 
nausea and anorexia (375 mg/m2); more than 2-week delay for thrombocytopenia 
(450 mg/m2). Drug-related grade 3 toxicity included emesis, increased ALT, 
hypersensitivity reactions (two patients each), and drug-induced thrombocytopenia (n 
= 1). Common mild to moderate toxicities included fatigue, nausea, diarrhea, emesis, 
headache, rash/pruritus, increased AST/ALT, and anorexia. 
 Pharmacokinetic analysis demonstrated no difference in tanespimycin kinetics 
with or without trastuzumab. Pharmacodynamic testing showed reactive induction of 
Hsp70 (a marker of Hsp90 inhibition) in lymphocytes at all dose levels. Antitumor 
activity was noted (partial response, n = 1; minor response, n = 4; stable disease > or 
= 4 months, n = 4). Tumor regressions were seen only in patients with human 
epidermal growth factor receptor 2 (HER-2)-positive metastatic breast cancer. 
Tanespimycin plus trastuzumab is well tolerated and has antitumor activity in patients 







Letrozole is a third-generation, nonsteroidal aromatase inhibitor. Adjuvant 
therapy with letrozole is more effective than tamoxifen in postmenopausal women 
with hormone-responsive early breast cancer, and extended adjuvant therapy with 
letrozole after the completion of adjuvant tamoxifen therapy is more effective than 
placebo in this patient population [75]. Letrozole is generally well tolerated too.   
Letrozole should be considered a valuable option in the treatment of postmenopausal 
women with hormone-responsive early breast cancer, both as adjuvant and extended 
adjuvant therapy [75] .One large randomized trial demonstrated that administration of  
letrozole to high-risk (node-positive) postmenopausal patients who have completed 5 
years' adjuvant  tamoxifen further prevents late recurrences and contralateral breast 
cancer, contrary to the lack of obvious benefit of extending tamoxifen treatment to 10 
years found in another large randomized study [91]. 
The PI3K/AKT/mTOR-pathway 
The phosphatidylinositol 3-kinase/protein kinase B/mammalian target of 
rapamycin-pathway (PI3K/AKT/mTOR-pathway) plays a role in the regulation of cell 
proliferation, cell survival, angiogenesis and resistance to anti-tumor treatments [92]. 
In many tumor types the PI3K/AKT/mTOR-pathway is found activated through 
several different underlying mechanisms. Since this pathway is believed to largely 
drive the malignant behavior of several of these tumors, mTOR-inhibition is 
considered an attractive means to apply as anti-tumor treatment. Currently, four 
mTOR-inhibitors are explored for clinical use: rapamycin, temsirolimus (CCI-779), 
everolimus (RAD001) and deforolimus (AP23573). As monotherapy, mTOR-
inhibitors yield interesting anti-tumor activity against various tumor types at the 
expense of relatively mild toxicities [92]. This recently resulted in the registration of 
two mTOR-inhibitors for patients with metastatic renal cell carcinoma (RCC) while 
randomized studies in other tumors are currently in progress. Furthermore, mTOR-
inhibitors are well-suited drugs to combine with other anti-tumor drugs as in 
preclinical models mTOR-inhibition overcomes chemo resistance. Consequently, 
mTOR-inhibitor-containing multidrug regimens are subject to clinical studies. As 
holds true for all anti-tumor therapies, identification of patients who are likely to 
respond to mTOR-inhibitor-containing therapies is of utmost importance to avoid 
over- or under treatment. Preliminary results suggest that several factors reflecting 
activation of mTOR in tumors may be used for this purpose [92]. 
Exemestane 
Exemestane is an orally active steroidal irreversible inactivator of the 
aromatase enzyme [93]. It is for an adjuvant treatment in postmenopausal women 
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with estrogen receptor-positive early-stage BC that it is following 2-3 years of 
adjuvant treatment with tamoxifen, and for the treatment of advanced BC in 
postmenopausal women whose their disease occurred by using tamoxifen or other 
antiestrogen therapy. In early-stage disease, switching to exemestane for 2-3 years 
after 2-3 years of adjuvant tamoxifen treatment was more effective in prolonging 
disease-free survival than continuing tamoxifen therapy, although it was not 
associated with an overall survival benefit, except in those with estrogen receptor-
positive or unknown receptor status disease when nodal status, hormone replacement 
therapy (HRT) and chemotherapy use were adjusted for [93]. Moreover, preliminary 
data suggest that the efficacy of exemestane is the same with tamoxifen in the primary 
adjuvant treatment of early-stage breast cancer, but exemestane may be better in 
prolonging the time to distant recurrence. In advanced disease, exemestane showed 
equivalent efficacy to megestrol in patients with disease refractory to tamoxifen and 
an efficacy not significantly different from that of fulvestrant in those refractory to a 
nonsteroidal aromatase inhibitor. Exemestane is also effective in the first-line 
hormonal treatment of advanced BC in postmenopausal women. Exemestane is 
generally well tolerated, although there is bone fracture risk. It is an emerging 
treatment option for postmenopausal women with advanced BC resistance to one or 
more antiestrogen therapies [92]. 
Fulvestrant 
Fulvestrant an estrogen receptor antagonist that has different and distinct mode 
of action and no agonist effects [94]   may offer an effective treatment option in the 
post-AI setting [95]. Four Phase III clinical trials in postmenopausal women with 
advanced BC have found fulvestrant at the approved dose of 250 mg/month to be at 
least as effective and well tolerated as anastrozole or [94] exemestane [96]  when 
following disease  progression or recurrence when using tamoxifen. In addition, 
fulvestrant has also demonstrated activity in patients with visceral and HER2+ 
disease, who are generally regarded as being less responsive to endocrine therapy. 
Data from a recent neoadjuvant study [96] shows that higher dose of fulvestrant may 
possess greater activity.  This systematic review was undertaken to examine and 
support if fulvestrant can be use as systemic therapy for metastatic or topically 
improved BC in postmenopausal women. Based on the findings, Fulvestrant can be 
considered as alternative therapy to anastrozole or exemestane in postmenopausal 
women with topically increased or metastatic BC [96].  
Comparison of anastrozole, letrozole and exemestane in the management of early 
breast cancer 
The hormonal therapy of patients with endocrine-sensitive early BC has 
mainly consisted, for several decades, of the gold standard tamoxifen [97]. The 
efficacy and favorable toxicity profiles of third-generation aromatase inhibitors (AIs), 
anastrozole, letrozole and exemestane, in advanced disease led to their development 
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in early breast cancer. Recent results consistently show the superiority of these agents 
over tamoxifen. Adjuvant trials by Nabholtz et al [97] evaluated AIs using four 
different therapeutic approaches: (1) Upfront strategy: randomization of newly 
diagnosed patients: tamoxifen for 5 years versus AI for 5 years, (2) Sequential 
strategy: randomization of newly diagnosed patients: tamoxifen (2 - 3 years) followed 
by AI or the inverse for a total of 5 years versus upfront AI for 5 years, (3) Switch 
strategy: delayed randomization (or analysis) after 2 - 3 years of tamoxifen (patients 
free of disease): 2 - 3 years of tamoxifen versus 2 - 3 years of AI (total treatment 5 
years) and (4) Extended strategy: delayed randomization after 5 years of tamoxifen 
(patients free of disease): 2 - 5 years of AI versus placebo.  
Overall, AIs showed evidence of superiority over tamoxifen in the adjuvant 
setting with proven improved efficacy and better toxicity profile. Despite some 
common characteristics, a body of evidence on AIs indicates some specific 
differences between the three agents in mechanism of action, pharmacokinetics, 
efficacy as well as toxicity profiles [97]. Consequently, these hormonal agents may 
not be considered interchangeable in clinical practice. This review explores available 
results from AI trials and tries to define their present role in the adjuvant management 
of postmenopausal patients with BC [97]. 
Monoclonal Antibodies  
Bevacizumab 
Bevacizumab is a humanized monoclonal antibody to VEGF, and the 
incorporation of bevacizumab to chemotherapy is one of the rapidly evolving areas in 
the treatment of breast cancer. Preclinical studies have shown that Bevacizumab 
(Avastin) in combination with chemotherapy versus chemotherapy alone improves 
progression-free survival and increases the response rate in first-line therapy for 
locally recurrent or metastatic breast cancer. This approach has been and is still being 
evaluated for early BC in neoadjuvant and adjuvant settings. Bevacizumab is well 
tolerated and has an established tolerability profile. The biomarkers of benefit will 
ultimately help identify the subgroups of patients who specifically benefit from anti-
VEGF therapy with bevacizumab [68].  Vascular endothelial growth factor (VEGF) 
has emerged as a key target for the treatment of cancer. As the ligand to the VEGF 
receptor, it plays a central role in promoting tumor angiogenesis. Over expression of 
VEGF leads to poor outcomes in patients with BC and other tumors. As a single agent 
or added to vinorelbine, bevacizumab has produced encouraging results in phase II 
clinical trials in patients with refractory metastatic breast cancer. When added to 
capecitabine chemotherapy in a phase III trial, bevacizumab produced a greater 
response rate, but did not prolong progression-free survival. This may reflect the late 
disease stage and poor prognostic factors in the patient population. A large, ongoing, 
phase III, cooperative group trial is evaluating the effect of bevacizumab in 
combination with paclitaxel as first-line therapy for metastatic disease. The adverse 
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effect profile of bevacizumab differs from that of cytotoxic chemotherapy and 
includes hypertension, proteinuria, thrombosis, and epistaxis [80]. 
Cetuximab and Panitumunab 
Numerous cellular pathways have a significant impact in the growth and 
metastatic potential of tumors [81]. Essential element of such pathways is the 
epidermal growth factor receptor (EGFR), a member of the HER family of receptor 
tyrosine kinases. One of the most important issues in cancer, which attracted the 
attention of clinical oncologists, is the potential use of targeted therapies. EGFR 
signaling pathway is implicated in the control of cell survival, proliferation, 
metastasis and angiogenesis. EGFR is, therefore, an appealing target for molecular-
targeted cancer therapy as it is expressed in a variety of solid tumors (colorectal, 
breast, head and neck, etc.). Receptor antagonists that target EGFR have already been 
of high interest for a number of years [81]. Multiple therapeutic strategies have been 
developed to target EGFR, including monoclonal antibodies (mAbs), tyrosine kinase 
inhibitors (TKIs), ligand-toxin conjugates, and antisense oligonucleotides. In 
particular, mAbs block ligand from binding to the extracellular domain of the 
receptor. Two mAbs that block EGFR (erbB1), cetuximab and panitumumab, have 
been approved by FDA. Cetuximab is a chimeric IgG1 anti-EGFR monoclonal 
antibody, whereas panitumumab is a fully human IgG2 anti-EGFR monoclonal 
antibody [81].  
Tyrosine kinase inhibitors 
Tyrosine kinases (TKs) are attractive targets for cancer therapy, as quite often 
their abnormal signaling has been linked with tumor development and growth [99]. 
Constitutive activated TKs stimulate multiple signaling pathways responsible for 
DNA repair, apoptosis, and cell proliferation. In the last few years, thorough analysis 
of the mechanism underlying tyrosine kinase's activity led to novel cancer therapy 
using TKs blockers [99,100]. These drugs are remarkably effective in the treatment of 
various human tumors including head and neck, gastric, prostate and Breast Cancer 
and leukemia. The most successful example of kinase blockers is Imatinib (Imatinib 
mesylate, Gleevec, STI571), the inhibitor of Bcr/Abl oncoprotein, which has become 
a first-line therapy for chronic myelogenous leukemia. The introduction of STI571 for 
the treatment of leukemia in clinical oncology has had a dramatic impact on how this 
disease is currently managed. Others kinase inhibitors used recently in cancer therapy 
include Dasatinib (BMS-354825) specific for ABL non-receptor cytoplasmic kinase, 
Gefitinib (Iressa), Erlotinib (OSI-774, Tarceva) and Sunitinib (SU 11248, Sutent) 
specific for VEGF receptor kinase, AMN107 (Nilotinib) and INNO-406 (NS-187) 
specific for c-KIT kinase. The following TK blockers for treatment of various human 
tumors are in clinical development: Lapatinib (Lapatinib ditosylate, Tykerb, GW-
572016), Canertinib (CI-1033), Zactima (ZD6474), Vatalanib (PTK787/ZK 222584), 
Sorafenib (Bay 43-9006, Nexavar), and Leflunomide (SU101, Arava)  [99]. 
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Alterations in tyrosine kinase expression or functionality have been linked to 
tumor growth, and detailed analysis of tyrosine kinase pathways has led to the 
development of novel anticancer drugs based on their inhibition.[98] The aim was to 
examine the cytotoxicity and cellular alterations correlated with multidrug resistance 
mechanisms induced by three tyrosine kinase inhibitors, lapatinib, sorafenib and 
gefitinib. The study was performed on three Breast Cancer cell lines (BRC-230, 
MCF-7 and SkBr3). Lapatinib and gefitinib induced a cytotoxic effect and 
mitochondrial membrane depolarization in BRC-230 and SkBr3 cells, while sorafenib 
induced apoptosis and a high and rapid dissipation of mitochondrial potential in all 
cell lines.[98] Moreover, all three drugs produced a rapid cytosolic calcium 
mobilization from endoplasmic reticulum stores in the investigated cell lines and a 
strong decrease in multidrug transporter activity in BRC-230 and MCF-7 cells. 
Mitochondrial membrane depolarization and inhibition of multidrug transporter 
activity induced by tyrosine kinase inhibitors were independent of cytosolic calcium 
mobilization. These data suggest that the investigated drugs possess mechanisms of 
action that are independent of drug target expression, opening up further possibilities 
for the development of new therapeutic strategies [98]. 
Lapatinib 
Lapatinib is an oral, small-molecule, that inhibits epidermal growth factor 
receptor (EGFR) and human epidermal growth factor receptor-2 (HER2) tyrosine 
kinases [101]  by binding to the ATP-binding site of the receptor's intracellular 
domain. This results in inhibition of tumor cell growth. The drug is relatively well 
tolerated in patients, with few and mostly low-grade adverse effects. In particular and 
unlike to trastuzumab, it has very little (if any) adverse effects on cardiac function 
[102] Some data show that lapatinib could cross the blood-brain barrier, with some 
evidence of activity in treating or preventing brain metastases [102] Recently, 
lapatinib  gained approval for use in the USA and Europe, for the use in combination 
with capecitabine in the treatment of advanced BC overexpressing HER2 (HER2+) 
and for the treatment of advanced HER2-positive breast cancer respectively [103, 
101] .  
Sunitinib 
Sunitinib is an orally available small-molecule multikinase inhibitor [104]. 
This agent potently inhibits the vascular endothelial growth factor receptor, platelet-
derived growth factor receptor, and c-Kit in addition to other kinases in biochemical 
and cell-based assays [105]. In several relevant preclinical cancer models, sunitinib 
exerts significant antiangiogenesis and antitumor effects.  
In phase I studies, using intermittent dosing schedules, oral administration of 
doses up to 50 mg/day were reasonably well tolerated and resulted in plasma 
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concentrations in the range of targeted levels needed for sustained kinase inhibition 
[100]. 
 Biomarker and functional imaging studies showed modulation of circulating 
markers of angiogenesis as well as a reduction in tumor metabolism. Sunitinib 
showed clinical activity in patients with renal cell cancer and in patients with 
imatinib-resistant gastrointestinal stromal tumors [100]. Definitive randomized 
clinical trials showed significant clinical activity in these two indications leading to 
regulatory approval [100]. In addition, this drug has showed activity in a variety of 
other tumor types such as breast, colon, and lung cancer and is being explored in 
combination with standard drugs in these diseases. The observation that biological 
and functional imaging effects are reduced during drug-free intervals has prompted 
the evaluation of protracted dosing schedules. A better understanding of mechanisms 
involved in resistance to sunitinib provides the rationale for combination strategies 
that hopefully will result in better clinical effect [100]. 
TP53        
 
TP53 encodes the tumor suppressor protein p53, which inhibits cell cycle 
progression in the presence of radiation-induced DNA breaks [107]. TP53 mutations 
are associated with a syndrome named Li-Fraumeni syndrome (LFS) and Li-
Fraumeni-like syndrome (LFLS) (see also Table 3) [106]. In families with LFS, TP53 
is frequently mutated. Studies have shown that although mutations in TP53 are 
extremely rare in the general population, those with the mutation will develop cancer 
at some point [106]. In a study of 100 women who had breast cancer, 4 women below 
31 years of age had a mutation in TP53, independent of BRCA-gene mutation status; 
2/37 familial BC cases had features of LFS or LFLS and 2/63 non-familial cases had 
mutations in TP53]. In Walsh‘s study] of 300 women with a strong family history of 
BC who had neither mutations nor genomic rearrangements within the BRCA1 and 
BRCA2 genes, three families had LFS and 7 families had LFLS. Two of the 3 
families with LFS and 1 in family history of Breast Cancer without LFS or LFLS, 
none carried mutations in TP53. In this selected population, about 1% of families with 










                                                                                                     
44 
 
Table 3 the criteria for LFS and LFLS syndromes that are associated with the TP53 mutations adapted 
from Rosman et al [106] 
Li-Fraumeni Syndrome (LFS) 
Sarcoma <45 years old with  1st degree relative < 45years old with cancer and 1st or 
2nd degree relative < 45years old  with any cancer  
Li-Fraumeni-like syndrome (LFLS) 





 degree relative with LFS tumor and 1st or 2nd degree relative 
< 60years old with cancer  
 
NeuVax 
Apthera is developing NeuVax which is a vaccine consisting of an 
immunogenic peptide derived from the HER2/neu protein which is over-expressed in 
many Breast Cancer patients [108,109]. It is in Phase II/III testing to treat early-stage, 
HER2-positive breast cancer and in Phase I/II testing to treat HER2-positive prostate 
cancer [109].  According to Apthera, patients demonstrated in vivo immunologic 
responses as well as in vivo DTH responses post-treatment. Clinical recurrence rate 
was 5.6% (5/90) for treated patients versus 14.8% (12/81) for the observation patients 
(p=0.04)[108].  
NeuVax can be administered safely and with minimal local or systemic 
toxicity. Both in vitro functional assays and in vivo DTH responses indicate a good 
immunologic response to the treatment. NeuVax appears to reduce rate of recurrence 
in disease-free conventionally treated BC patients. It may represent a useful adjunct to 
current standard therapy in reducing the rate of BC recurrence [109]. 
 8. Gene Therapy 
Gene therapy is a therapeutic approach that is designed to correct specific 
molecular defects that contribute to the cause or progression of cancer [111]. Genes 
that are mutated or deleted in cancers include the cancer susceptibility genes p53 and 
BRCA1. Because mutational inactivation of gene function is specific to tumor cells in 
these settings, cancer gene correction strategies may provide an opportunity for 
selective targeting without significant toxicity for normal non-tumor cells [111]. Both 
p53 and BRCA1 appear to inhibit cancer cells that lack mutations in these genes, 
suggesting that the so-called gene correction strategies may have broader potential 
than initially believed. Increasing knowledge of cancer genetics has identified these 
and other genes as potential targets for gene replacement therapy. Initial patient trials 
of p53 and BRCA1 gene therapy have provided some indications of potential 
efficacy, but have also identified areas of basic and clinical research that is needed 
before these approaches may be widely used in patient care [110]. 
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The BRCA1/2 mutations are the most commonly identified germ line gene 
mutations in patients with hereditary breast cancer [112]. These proteins have many 
critical cellular functions, including repair of DNA double-strand breaks. The role of 
defective BRCA1/2 as a predictor of response to DNA-damaging agents has been 
studied extensively in preclinical models, but prospective clinical validation is lacking 
[113, 114]. Poly [ADP-ribose] polymerase (PARP) inhibitors illustrate the concept of 
synthetic lethality in cells with defective BRCA1/2 and numerous PARP inhibitors 
are being evaluated in patients with BRCA1/2-associated tumors [115]. BRCA1/2 
mutation or functional loss will likely serve as a useful predictive biomarker of 
response to treatment with PARP inhibitor [117, 116]. 
 
Despite Gene therapy for cancer treatment representing a promising approach 
that has shown selectivity and efficacy in experimental systems as well as clinical 
trials, some major problems remain to be solved before this strategy becomes 
routinely adopted in the clinic. One of the main challenges being the improvement of 
gene delivery [118]. Namely, the development of DNA vectors characterized by 
maximum efficiency and minimal toxicity will define the success of gene therapy and 
its chances of being accepted by public and clinicians. A number of issues need to be 
considered. The "magic" vector should be targeted, protected from degradation and 
immune attack, and safe for the recipient and the environment. Moreover, it should 
express the therapeutic gene for as long as required, in an appropriately regulated 
fashion. Vehicles such as retroviruses, adenoviruses and liposomes have been adopted 
in clinical studies, with varying results. New therapeutic modalities are also being 
explored in order to overcome the limitation of poor gene transfer and patient toxicity, 
including bacteria, adeno-associated and herpes simplex viruses, lentiviruses, cationic 
polymer-DNA complexes and electroporation [118]. 
 
Once the mutation is identified in the gene, patients and their relatives have 
the option of preimplantation genetic diagnosis (PGD) in order to select embryos 
without familial cancer-predisposing mutations [119]. This procedure has already 
been performed in several syndromes, including the common syndromes of genetic 
predisposition to colon and breast cancer. Despite the numerous ethical objections and 
legal arguments, PGD for adult-onset cancers is today a reality and couples with an 
inherited predisposing mutation deserve the same respect, support and right to choose 
if their child will be born having an extremely high risk for cancer development as in 
the case of other life-threatening diseases for which prenatal screening has become a 
standard [97] Mutations within the BRCA1 and BRCA2 genes are common among 
women with a strong family history of breast cancer, they account for at most 3–8% 
of all BC cases. Mutations in the TP53 and PTEN genes, which cause Li- Fraumeni 
syndrome and Cowden syndrome respectively (as seen above), are exceedingly rare, 
and probably account for less than 0.1% of breast cancers. Other candidate genes that 
may cause BC have been identified in the past few years. Cancer susceptibility genes 
that are associated with an increased risk of BC include TGFBR1*6A, 
CHEK2*1100delC, and BRIP1 [120, 121]. 
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A recent analysis of 22 studies involving 8,139 index case patients unselected 
for family history shows that carrying a deleterious BRCA1 mutation confers an 
estimated lifetime risk for developing BC of 65% (95% CI 44–78%) [122]. By the age 
of 40, carrying a deleterious BRCA1 mutation confers a 20% chance of developing 
breast cancer, and the risk increases with age, with the lifetime risk being 82% by the 
age of 80. In a combined analysis of 22 studies, BRCA2 mutation carriers were found 
to carry a cumulative BC risk by age 70 of 45% (95% CI = 31% – 56%), and for 
ovarian cancer of 11% (95% CI = 2.4%–19%) [123]. 
 
ERBB3-protein family or epidermal growth factor receptor (EGFR) family 
ERBB3, a member of the epidermal growth factor receptor (EGFR) family, is 
unique in that its tyrosine kinase domain is functionally defective [123]. It is activated 
by neuregulins, by other ERBB and non ERBB receptors as well as by other kinases, 
and by novel mechanisms [131].  
There are likely important but poorly understood roles for nuclear localization 
and for secreted isoforms. Studies of ERBB3 expression in primary cancers and of its 
mechanistic contributions in cultured cells have implicated it, with varying degrees of 
certainty, with causation or sustenance of cancers of the breast, ovary, prostate, 
certain brain cells, retina, melanocytes, colon, pancreas, stomach, oral cavity and lung 
[120]. Recent results link high ERBB3 activity with escape from therapy targeting 
other ERBBs in lung and breast cancers [124]. 
MicroRNAs 
MicroRNAs (miRNAs) are small 20-22 nucleotide-long members of the non-
protein-coding RNA family and cause an inhibition of translation and some degree of 
degradation of the target messenger RNAs (mRNAs) through binding to partially 
complementary sites, usually in the 3' untranslated regions of the target mRNAs 
[189]. Therefore, miRNAs play pivotal roles as negative regulators of gene expression 
in a wide array of physiological processes.  
Recent observations reveal that many miRNAs have been implicated in 
various human cancers. Both losses and gains of miRNA function have been shown to 
contribute to cancer development through a variety of mechanisms [182].  
In oncology, detection and monitoring of tumors are now becoming possible 
by the evaluation of tumor-derived secretory miRNAs. However, the secretory 
mechanism and biological function of extra cellular miRNAs remain unclear.  
The fact that several miRNA genes are dysregulated in multiple types of 
cancer indicates that significant pathways involved in tumorigenesis may have 
miRNAs as downstream targets. Thus, in tumors where miRNA genes are lost or 
amplified, miRNA mimetics or antagomirs, respectively, are considered as promising 
drugs to induce apoptosis and/or cell cycle arrest in cancer cells that depend on 
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miRNA dysregulation for growth and survival. There is growing evidence that 
miRNA therapy could be a potent means to curtail tumor growth [191]. 
MYC proteins 
MYC proteins (c-MYC, MYCN, and MYCL) regulate processes involved in 
many if not all aspects of cell fate. Therefore, it is not surprising that the MYC genes 
are deregulated in several human neoplasias as a result from genetic and epigenetic 
alterations [127]. MYC encodes a transcription factor that, as part of a heterodimeric 
complex with MAX, regulates the expression of a multitude of genes involved in 
regulating cellular proliferation and growth [129, 128]. 
The near "omnipotency" together with the many levels of regulation makes 
MYC an attractive target for tumor intervention therapy [127]. Overexpression of 
MYC is commonly associated with tumorigenesis. MYC exerts its neoplastic function 
by inducing autonomous cellular proliferation and cellular growth, blocking 
differentiation, and inducing genomic destabilization [128]. 
T cell receptor 
T cell receptor (TCR) gene therapy provides patients with autologous T cells 
that are genetically engineered with TCR alphabeta chains and constitutes a promising 
approach for the treatment of tumors and virus infections.[129] Among the current 
challenges of TCR gene therapy is the optimization of TCR alpha and beta transgene 
pairing to enhance the functional avidity of therapeutic T cells. Recently, various 
genetically modified TCRs have been developed that enhance TCR pairing and 
minimize mispairing, i.e. pairing between transgenic and endogenous TCR chains. 
[130]. 
p53 gene therapy 
 
The p53 is the most commonly mutated tumor suppressor gene in solid tumors 
and is also mutated in the germline of patients with the rare hereditary Li-Fraumeni 
syndrome [105]. The p53 gene is specifically relevant to the development and 
progression of breast cancer, because p53 is frequently mutated in BC specimens and 
Li-Fraumeni syndrome patients develop BC as part of their multiple cancer syndrome. 
Thus, p53 genetic correction is a rational approach for breast cancer, particularly in 
those rare patients with BC as part of Li-Fraumeni syndrome [107].  
 
The function of wild-type p53 is suppression of cell proliferation through a 
multiprotein regulatory pathway that is focused around the retinoblastoma gene and 
control of apoptosis [116].Because p53 may naturally function as an inhibitor of cell 
proliferation, it inhibits cell growth in most normal and malignant cells, with few 
exceptions [119,120, 121]. For this reason it may effectively inhibit tumor growth 
even in cancers that do not have p53 mutations .Preclinical animal studies of 
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adenovirus-based p53 gene therapy for cancer in both cell culture and animal models 
have demonstrated tumor suppression [107]. 
 
BRCA1 gene therapy 
 
Although the molecular function of BRCA1 is controversial and may include 
DNA repair or transcriptional functions, overexpression of BRCA1 into sporadic 
breast or ovarian cancer cells, which usually show low BRCA1 expression, results in 
growth inhibition and tumor suppression [122,123].  
 
The mechanism of growth inhibition by BRCA1 is unknown and may involve 
interactions with WAF1/CIP1, p53, Rb or induction of apoptosis. Although BRCA1 is 
only mutated in a small percentage of breast or ovarian cancers, the majority of 
sporadic breast and ovarian cancers appear to express low levels of BRCA1 
messenger RNA and protein. This appears to be a consequence of loss of 
heterozygosity and promoter methylation of the remaining BRCA1 allele [124, 125]. 
 
PTEN       
 
The PTEN (phosphatase and tensin homolog) is a tumor suppressor gene that 
inhibits cell growth during the G1 phase of cell cycle by activating the cyclin-
dependant kinase inhibitor p27 (KIP1) .Mutations in PTEN are rare, but are associated 
with a high penetrance syndrome termed Cowden disease (CD). Individuals with 
Cowden syndrome have a high risk for developing BC as well as hamartomas and 
benign tumors in the skin, thyroid, breast, endometrium, and brain. At least three 
different mutations in PTEN have been found in families with CD and early onset of 
Breast Cancer [80].  
9. Stem Cells Therapy 
Stem cells are the natural sources of embryogenesis and continuous 
regeneration throughout adult life [132]. Stem cells provide for life-long cell 
replacement in tissues and organs, and have inherent homing abilities that are critical 
in therapeutic applications. Stem cells are also the driving force of cancer where 
genetic/epigenetic alterations culminate in tumorigenesis either in tissue stem cells or 
in some of their derivatives.[132] As a rare subset of the tumor, cancer stem cells are 
the only drive of tumor initiation/propagation. Autologous and cancer stem cells are 
thus the key targets of a) long-term and transient-regenerative/epigenetic gene therapy 
and b) of recurrence-free anticancer therapy, respectively [132, 133].  
Stem cells can be distinguished from other cell types based on two unique 
characteristics. First, they are unspecialized cells capable of renewing themselves 
through cell division, sometimes after long periods of inactivity. Second, under 
certain physiologic or experimental conditions, they can be induced to become tissue- 
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or organ-specific cells with special functions. In some organs, such as the gut and 
bone marrow, stem cells regularly divide to repair and replace worn out or damaged 
tissues. In other organs, however, such as the pancreas and the heart, stem cells only 
divide under special conditions [133]. 
Scientists around the world, primarily work with two types of stem cells from 
animals and humans: embryonic stem cells and non-embryonic "somatic" or "adult" 
stem cells [134]. In 1998, scientists developed a method to derive stem cells from 
human embryos and grow the cells in vitro. These cells are called human embryonic 
stem cells [135]. The embryos used in these studies were created for reproductive 
purposes through in vitro fertilization procedures. In 2006, researchers identified 
conditions that would allow some specialized adult cells to be "reprogrammed" 
genetically to assume a stem cell-like state. This new type of stem cell is called 
induced pluripotent stem cells (iPSCs) [135]. 
Stem cell therapy is the replacement of diseased, dysfunctional or injured cells 
with either adult or embryonic stem cells [134]. It's somewhat similar to the organ 
transplant process but uses cells instead of organs. Stem cell therapy is sometimes 
called regenerative medicine. The stem cells are manipulated to specialize them into 
specific types of cells, such as heart muscle cells, blood cells or nerve cells. This 
manipulation may involve changing the material in which the stem cells are grown or 
even injecting genes into the cells. The specialized cells could then be implanted into 
a person [135]. 
Recently, a model promised to find the way to explain the different biological 
features of breast cancer cell populations and their different response to therapeutic 
agents. This model links the emergence of breast cancer cells to stem cells and 
progenitors, an observation originally made in other cancer entities. It is supporting 
that tumors are coming from a small population of undifferentiated cells. These cells 
can undergo self-renewal and are able to generate a large number of partially 
differentiated cells, which constitute the mass of the tumor. If breast cancer is a stem 
and progenitor cell disease, this will have important implications for the 
understanding of the emergence of cancer cells. A combination between stem cells, 
early or late progenitors and the particular oncogenic mutations acquired can give a 
new classification to the different types of breast cancer. So these parameters might 
determine the mechanisms of cancer progression and the responsiveness of patients to 
drug treatment [183]. 
Whereas human breast epithelial stem cells may exist within the basal layer, 
the luminal compartment or its reprogrammed equivalent can provide precursor cells 
for breast cancer [184]. 
Understanding the origin of breast cancer stem cells, their relationship to 
breast cancer development, and the differences between normal and cancer stem cells 
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may lead to novel approaches to breast cancer diagnosis, prevention, and treatment 
[185]. 
  Multidrug Resistance – MDR  
1. Definition  
  
Multidrug resistance (MDR) in tumor cells is a significant obstacle to the 
success of chemotherapy in many cancers. Multidrug resistance is a phenomenon 
whereby tumor cells in vitro that have been exposed to one cytotoxic agent develop 
cross-resistance to a range of structurally and functionally unrelated compounds 
[136].  
MDR is termed 'intrinsic' when the disease is refractory to chemotherapy from 
the outset, or 'acquired' when the disease becomes insensitive to treatment upon 
relapse [137]. Multidrug resistance can affect patients with a variety of blood cancers 
and solid tumors, including breast cancer. Tumors usually consist of mixed 
populations of malignant cells, some of which are drug-sensitive while others are 
drug-resistant. Chemotherapy has the ability to destroy only the drug-sensitive cells, 
leaving however the drug-resistant cells unharmed. As a result the tumor begins to 
grow again, and chemotherapy fails because the remaining tumor cells are now 
resistant [137]. 
 
2. Etiology of multidrug resistance 
 
A number of different mechanisms can mediate the development of MDR, 
including increased drug efflux from the cell by adenosine triphosphate (ATP)-
dependent transporters, decreased drug uptake into the cell, activation of detoxifying 
enzymes, and defective apoptotic pathways. The presence of at least two molecular 
―pumps‖ in tumor-cell membranes that actively expel chemotherapy drugs from the 
interior are correlated to resistance to therapy [138]. This allows tumor cells to avoid 
the toxic effects of the drug or molecular processes within the nucleus or the 
cytoplasm. The two pumps commonly found to confer chemoresistance in cancer are 
P-glycoprotein (also referred to as MDR1 and ABCB1 according to the gene 
classification) and the multidrug resistance associated protein (also referred to as 
MRP). Because of their function and importance, they are the targets of several 
anticancer efforts. 
  
Active drug transporters such as MRPs (MDR associated proteins) and MDR1 
have been described in both prokaryotic and eucaryotic cells. According to Seral et al 
[129] these were originally described as conferring resistance to anticancer agents in 
cancer cells, antibiotics in bacteria, or antifungal agents in fungi, these proteins appear 
today to be part of a very general mechanism that cells have developed to protect 
themselves from invasion by diffusible, foreign molecules. The P-glycoprotein and 
MRP transporters belong to the family of ATP binding cassette transporters and use 
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ATP hydrolysis as an energy source [139]. They play a key role in drug disposition by 
modulating drug transport through epithelia and other biological barriers to an extent 
that was completely unsuspected before [140]. 
 
P-glycoprotein (P-gp) is a cell membrane-associated protein that transports a 
variety of drug substrates [141]. Although P-gp has been studied extensively as a 
mediator of multidrug resistance in cancer. However, P-gp is expressed in normal 
tissues as well and acts as a determinant of drug pharmacokinetics. P-glycoprotein is 
present in organ systems that influence drug absorption (intestine), distribution to site 
of action (central nervous system and leukocytes), and elimination (liver and kidney), 
as well as several other tissues. Many marketed drugs inhibit P-gp function, and 
several compounds are under development as P-gp inhibitors. Similarly, numerous 
drugs can induce P-gp expression. While P-gp induction does not have a therapeutic 
role, P-gp inhibition is an attractive therapeutic approach to reverse multidrug 
resistance. Clinicians recognize that P-gp induction or inhibition may have a 
substantial effect on the pharmacokinetics and pharmacodynamics of concomitantly 
administered drugs that are substrates for this transporter [141].  
 
P-gp belongs to the ATP-binding cassette (ABC) family of transporters, 
currently numbering 48 members that share sequence and structural homology [142]. 
It is believed that, while this class of transporters has a large number of members, 
only 10 or so are reported to confer the drug-resistant phenotype [143]. These 
transporters use the energy that is released when they hydrolyze ATP to drive the 
transport of various molecules across the cell membrane [1402]. In addition to their 
physiologic expression in normal tissues, many are expressed and, importantly, over-
expressed, in human tumors. Their role in the development of MDR and in normal 
tissues has been reviewed elsewhere [143]. 
 
In cancerous tissue, the expression of P-gp is usually highest in tumors that are 
derived from tissues that normally express P-gp, such as epithelial cells of the colon, 
kidney, adrenal, pancreas, and liver, resulting in the potential for resistance to some 
cytotoxic agents before chemotherapy is initiated. In other tumors, the expression of 
P-gp may be low at the time of diagnosis but increases after exposure to 
chemotherapy agents, thereby resulting in the development of MDR in those cells 
[144]. There is a growing body of literature that links the failure of certain 
chemotherapeutic agents to the expression of P-gp. Indeed, the induction of MDR1 
RNA can be rapid following exposure of tumor cells to chemotherapy [145].  
 
As mentioned earlier, increased Pgp is not the only cause of MDR. Several 
cell lines selected for resistance do not contain increased amounts of Pgp but 
nevertheless are resistant to a broad range of natural-product drugs [146-149]. In one 
of these non-Pgp MDR lines, the H69AR small-cell lung carcinoma (SCLC) line, 
Cole et al. [150] found amplification and increased expression of MRP genes. There 
are currently 9 isoformic members of MRP proteins (MRP1-6 = ABCC1-6 and MRP 
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7-9 = ABCC10-12).  Overexpression of MRP has since been observed in several other 
[151-153], but not all [151], non-Pgp MDR cell lines. Transfection of HeLa cells with 
an expression vector containing the MRP cDNA results in the acquisition of 
resistance to doxorubicin, vincristine, and VP-16, but not cisplatin [154]. Here it is 
shown that transfection of the MRP cDNA into human lung carcinoma cells also 
results in MDR. MRP belongs to the ABC superfamily of transporter proteins 
[150,155], and therefore one could claim that it could simply act like Pgp, as a plasma 
membrane pump extruding drugs. This claim is partially supported by the literature 
[154] which demonstrates decreased drug accumulation for several non-Pgp MDR 
cell lines that were later found to overexpress MRP [151-153]. However, there 
appears to be an exception to this rule. The exception is the MDR H69AR cell line in 
which the MRP gene was discovered [150]. Drug accumulation was reported to be the 
same as in the parental cell line and this led Cole et al. [141, 157, 158] to consider 
other mechanisms than decreased drug accumulation for MRP action. Moreover, the 
subcellular location of MRP did not seem to be similar to that of a plasma membrane 
transporter such as Pgp. A 190-kDa protein detected in non-Pgp MDR cells and 
thought to be MRP was found mainly in the endoplasmic reticulum, rather than in the 
plasma membrane [153]. 
 
A study by Zaman et al al [155] set out to investigate the exact mechanism by 
which MRP acts. They concluded that MRP is remarkably similar to the drug-
transporting Pgps in its mode of action: 
 
(a) Like Pgp, MRP can cause resistance to a range of hydrophobic drugs. 
(b) MRP is predominantly located in the plasma membrane. 
(c) MRP can decrease drug accumulation in the cell and this decrease is abolished by 
permeabilization of the plasma membrane.  
(d) MRP can increase the efflux of drugs from cells.  MRP is believed to act as a drug 
pump, like Pgp, extruding hydrophobic compounds from cells against a concentration 
gradient. Presumably the two ATP-binding motifs in MRP allow the protein, just like 
Pgp, to use ATP hydrolysis for active transport [155]. 
 
The BCRP is 95-kDa phosphoglycoprotein drug transporter of a somewhat different 
structure [159]. BRCP differs from Pgp and MRP because it contains only one 
transmembrane and one ATP binding domain, however its mode of action remains 
quite similar to those of Pgp. It is classified as the ABCG2 transporter , the ATP-
dependent pump belonging to the G subfamily of ABC transporters [159]. 
In a study by Litman et al, there were developed four polyclonal antibodies 
that were against peptides corresponding to four different epitopes on the 
mitoxantrone resistance- associated protein, ABCG2. Three epitopes on the 
cytoplasmic region of ABCG2 gave rise to high-affinity antibodies, which were 
demonstrated to be specific for ABCG2. The Western blot analysis of cells with high 
levels of ABCG2 showed a single major band of the expected 72-kDa molecular size 
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of ABCG2 under denaturing conditions.  The Immunoblot analysis was performed 
under non-reducing conditions and after treatment with cross-linking reagents there 
was a shift in the molecular weight from 72 kDa to several bands of 180kDa.  
Evidence of N-linked glycosylation was also obtained using tunicamycin and N-
glycosidase F. Fluorescence and electron microscopic immunohistochemical staining, 
showed cytoplasmic and predominantly plasma membrane localization of ABCG2 in 
cell lines with high levels of expression. Also there was an observation about staining 
of plasma membrane on the surface of the chorionic villi in placenta.                                                        
The conclusion was that ABCG2 is an ABC half-transporter of the G subfamily that 
can forms dimers in the plasma membrane and functions as an ATP-dependent 
outward pump for substrate transport [187 ]. 
In another study of Litman et al about ABCG2, was shown that ABC half-
transporter is a potent, new mechanism for conferring multiple drug resistance. They 
used four multidrug-resistant human colon (SI) and breast (MCF-7 ) cancer cell lines. 
Despite the different selection history of the colon and breast cancer sublines a similar 
phenotype was displayed. The cross-resistance patterns seem to be almost identical 
for the two sublines. Both had high level of resistance to mitoxantrone, the 
anthracyclines and topotecan. Then as visualized by microscopy, sublines  had similar 
intracellular drug distribution profiles with reduced mitoxantrone, daunorubicin, 
bisantrene, topotecan, BODIPY-prazosin and rhodamine 123. The restoration of 
mitoxantrone accumulation to the level in sensitive, parental cells after preincubation 
with azide and deoxy-glycose shown that the mitoxantrone resistance was correlated 
with that of an energy-dependent accumulation defect in both sublines. The efflux of 
mitoxantrone after restoration of energy was higher from the resistant cells that from 
the parental cell lines. According to a previous finding that transfection of the BCRP 
gene conferred mitoxantrone resistance to parental cancer cells is further confirming 
BCRP/MXR as the mechanism of resistance in these cells, Litman et al demonstrated 
that these cells exhibit decreased mitoxantrone accumulation as compared to control 
cells transfected with the vector alone. They further demonstrated that MXR-
expressing cells are capable of glucuronidating cytotoxic drugs.[189] 
In the recent years another type of drug transporter has been recognized which 
is not associated with the cytoplasmic membrane, but operates by controlling the drug 
transport from the nucleus to the cytoplasm via vaults. This is a 110-kDa vault 
protein, the lung resistance protein (LRP) [159]. Its drug substrate spectrum is similar 
to that of Pgp.  
 
A study was designed to determine whether BCRP is expressed at a 
mitochondrial level and to see its function in various MDR and parental drug-
sensitive cell lines. Experiments like Western blot analysis, immunofluorescence 
confocal and electron microscopy, flow cytometry analysis, and the BCRP (ABCG-2) 
small interfering RNA, showed that BCRP is expressed in the mitochondrial cristae 
and is functionally active there. In comparison to parental drug-sensitive cells 
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Mitoxantrone accumulation was significantly reduced in mitochondria and in cells 
that overexpress BCRP. In comparison with basal conditions in both whole cells and 
in mitochondria of BCRP-overexpressong cell lines, the specific inhibitor of BCRP, 
fumitremorgin c, increased the accumulation of mitoxantrone . So the conclusion of 
this study is that  BCRP is overexpressed and functionally active in the mitochondria 
of MDR-positive cancer cell lines. Also BCRP can be involved in the physiology of 
cancer cells because its presence in the mitochondria of parental drug-sensitive cells 
[188] . 
 
  3. Strategies to overcome multidrug resistance 
 
Scientists around the world have been struggling to develop nontoxic agents 
that would overcome the MDR of tumors. The way to achieve this incorporates 
various strategies, based on diverse mechanisms and effects. According to Borowski 
et al [159] these strategies use two general approaches: (a) rational design of agents 
that retain their cytostatic activity towards MDR tumor cells, and (b) development of 
augmenting compounds able to restore the cytotoxicity of available antitumor drugs 
against resistant cells. The latter approach is aimed at interfering with either the 
expression of the transporter proteins or their functioning. 
  
Control of expression of MDR protein 
  
Since its amplification is not a prerequisite for Pgp-related resistance in human 
tumor cells [160]. 
An MDR1 specific polypeptide transcriptional repressor has been screened out. 
Modification of MDR1 promoter region was achieved by 5-azacytidine [161].In 
consequence, the transcriptional activity was inhibited, and resistant K562 cells were 
transformed to a non-MDR type. Interesting results were obtained with ecteinascidin 
743, an isoquinoline derivative of marine origin [159]. This cytostatic agent of high 
activity selectively inhibits the activation of induced MDR1 gene blocking its 
transcription, without affecting constitutive MDR1 expression [162]. 
 
Overcoming the activity of MDR membrane transporter proteins 
 
There are several general strategies to circumvent the drug efflux action of 
expressed MDR transporter proteins. These strategies may include the: (a) 
development of compounds that are not substrates of the efflux pump(s), (b) use of 
agents that inactivate (inhibit) MDR proteins, (c) design of cytostatics characterized 
by fast cellular uptake, surpassing their MDR-mediated efflux, and the (d) use of 
compounds competing with a drug for the MDR protein mediated efflux [159].  
In order to overcome MRP and LRP resistance certain specific strategies have 
also been implemented. Reducing the MRP resistance can be achieved by affecting 
the intracellular formation of anionic drug conjugates. The formation of such 
conjugates with glutathione can be indirectly inhibited by buthionine sulfoximine 
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(BSO), a potent inhibitor of glutathione synthesis [163], or by the inhibition of 
glutathione reductase by N,N-bis(2-chloroethyl)-N-nitrosourea (BCNU) [164]. 
Inhibition of drug transport from the nucleus to the cytoplasm, mediated by LRP 
protein, was achieved with the PAK-104P inhibitor, a pyridine derivative [165].  
 
First Generation inhibitors of P-glycoprotein include: verapamil, cyclosporin 
(cyclosporin A), tamoxifen, and several calmodulin antagonists and worked by 
competing with the cytotoxic compounds for efflux by the P-gp pump. 
 
Second Generation inhibitors of P-glycoprotein include: dexverapamil, 
dexniguldipine, valspodar and biricodar. 
 
Third Generation inhibitors of P-glycoprotein include: the anthranilamide 
derivative tariquidar, the cyclopropyldibenzosuberane zosuquidar , laniquidar and the 
substituted diarylimidazole  [186 ]. 
 
Inhibiting P-gp as a way of reversing MDR has been extensively studied for 
more than 2 decades. Many agents that modulate the function of P-gp have been 
identified, including calcium channel blockers, calmodulin antagonists, steroidal 
agents, protein kinase C inhibitors, immunosuppressive drugs, antibiotics, and 
surfactants [136]. Perhaps the biggest impetus for pursuing the use of MDR 
modulators in the clinical setting was provided by the work of Chan et al [166-168] 
who first showed that the expression of P-gp was a significant prognostic marker in 
certain childhood malignancies. 
 
In patients with retinoblastoma they then used cyclosporin in combination 
with chemotherapy and achieved a high cure rate (91% of previously untreated 
patients remained relapse-free, with salvage therapy combining cyclosporin and 
chemotherapy prolonging survival in those previously untreated with cyclosporin) 
[168] . Although these trials were limited in size, they raised substantial interest in the 
cancer research community. However, it is now widely acknowledged that the major 
limitation of many of the early agents is that they typically reverse MDR at 
concentrations that result in unacceptable toxicity [169, 170]. This, together with 
unfavorable pharmacokinetic interactions, prompted the development of a number of 











Alternative ways of addressing the multidrug resistance 
 
An approach to deal with MDR cells is based on Monoclonal antibodies. 
These were initially used to identify the expression of Pgp, however, they can also be 
applied to inhibit Pgp specifically because of their high selectivity against well 
defined epitopes, and the resulting ability to abolish the MDR phenotype of tumor 
cells [159, 171]. 
 
Combining the anti-Pgp monoclonal antibodies with Pgp modulators may also 
be useful in enhancing the reversal of Pgp-mediated multidrug resistance [170]. 
Monoclonal antibodies themselves also affect the proliferation of Pgp-expressing 
tumor cells. A combination therapy using a monoclonal antibody, chemosensitizers, 


































IV . Conclusion  
Breast Cancer belongs among the most common types of cancer worldwide, 
furthermore the incidence of this disease is increasing in all countries. Comparing to 
previous years the discoveries on the treatment are in flare. Many drugs are used 
today and many others are under clinical trials.  
The approach of oncologists in the treatment of breast cancer traditionally 
follows the sequence: surgery-radiotherapy-chemotherapy.  
The specific receptors of cancer cells like estrogen receptor, progesterone 
receptor and human epidermal growth factor predetermine the choice of therapy. 
Clinical studies have demonstrated that the presence of such receptors formthe 
etiology and explaines why a number of women with Breast Cancer respond to 
hormonal therapy or immune therapy and why others do not.  
The development of drugs that use the pathways of immune system to induce 
their effect, like interferon and monoclonal antibodies or vaccines  have recently 
started to successfully contribute to the fight against cancer. For example the vaccine 
NeuVax is an example of immune therapy that reduces the recurrence in patients 
while it is administered with minimal local and systemic toxicity. The very novel 
approaches to treat breast cancer play on gene therapy as the strategy that effort to fix 
the mutations in genes that predestine women to fall ill with breast cancer. Studies 
also showed that the combination of some of the available drugs and therapies can 
maximize the effects of the treatment. For example, the combination of tyrosine 
kinase inhibitors and monoclonal antibodies with trastuzumab is a representative 
example of the possible combinations. Other combinations reported in the literature 
include the adjuvant therapy with letrozole which is more effective than tamoxifen in 
postmenopausal women with hormone-responsive early breast cancer, and extended 
adjuvant therapy with letrozole after the completion of adjuvant tamoxifen therapy 
which is more effective than placebo in this patient population. Furthermore, 
exemestane is used as an adjuvant treatment in postmenopausal women with estrogen 
receptor-positive early-stage BC that follows 2-3 years of adjuvant treatment with 
tamoxifen, and for the treatment of advanced BC in postmenopausal women, whose 
disease occurred by using tamoxifen or other antiestrogen therapy.  
Despite there are many ―weapons‖ available in the ―arsenal‖ against cancer, 
these are not without side-effects. Every treatment available appears with related side-
effects, which can be mild to severe. In fact in some cases, these can be so severe that 
can lead to the termination of the treatment followed and alternatives considered.  
Anticancer therapy often fails through the multidrug resistance of tumor cells. 
This phenomenon can be caused by transport activity of efflux pumps localized to the 
cellular membrane. Therefore an intensive effort is put also into the search of 
substances or mechanisms that could reverse the resistance and make the tumor cells 
sensitive to the anticancer therapy. 
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Until the time when the cure of cancer will be discovered by scientists, the 
cancer journey continues, with its‘ ups and downs in the treatments available. 
However, the knowledge is the tool that healthcare workers need in their effort to 
choose the best available and individually tailored therapeutic approach to breast 
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